[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dlbcl---diffuse-large-b-cell-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dlbcl---diffuse-large-b-cell-lymphoma":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,41,0,25,[9,43,68,94,118,138,157,177,204,226,252,273,301,326,352,397,419,440,461,484,506,530,561,579,613],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100652781","orelabrutinib-combined-with-pola-r-chp-as-first-line-treatment-for-patients-with-intermediate--to-high-risk-dlbcl-100652781",false,"NCT07778212","Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL","A Translational Study of Orelabrutinib Combined With Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) as First-Line Treatment for Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)","Inclusion Criteria:\n\n1. Aged ≥ 18 years;\n2. Pathologically confirmed diffuse large B-cell lymphoma (DLBCL) by tumor tissue, with at least one measurable lesion, including DLBCL, not otherwise specified (GCB and non-GCB subtypes), DLBCL with MYC and BCL-2 rearrangements, and high-grade B-cell lymphoma;\n3. No prior receipt of other anti-tumor treatments;\n4. ECOG performance status 0-2;\n5. IPI score 2-5, and patients with stage III-IV disease;\n6. Life expectancy ≥ 6 months;\n7. Voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Lymphoma involving the central nervous system or leptomeningeal metastasis;\n2. Transformed lymphoma, i.e., transformed from other types of lymphoma, such as follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, or small B-cell lymphoma;\n3. Primary mediastinal large B-cell lymphoma;\n4. Burkitt lymphoma;\n5. Left ventricular ejection fraction \\\u003C 50%;\n6. Laboratory test values at screening: (unless caused by lymphoma);\n\n   1. Neutrophils \\\u003C 1.5×10⁹\u002FL;\n   2. Platelets \\\u003C 75×10⁹\u002FL;\n   3. ALT or AST higher than 2 times the upper limit of normal, AKP and bilirubin higher than 1.5 times the upper limit of normal;\n   4. Creatinine level higher than 1.5 times the upper limit of normal;\n7. Patients with psychiatric disorders or other patients who are known or suspected to be unable to fully comply with the study protocol;\n8. Pregnant or lactating women;\n9. Known infection with human immunodeficiency virus (HIV), or active hepatitis B or C virus infection (positive result by polymerase chain reaction \\[PCR\\]). If a patient has a positive HBsAg test result, HBV DNA testing is required. If HBV DNA \\\u003C 10³ IU\u002Fml, the patient can be enrolled. If the HBsAg test result is negative, but the HBcAb test is positive (regardless of HBsAb status), HBV DNA testing is also required. If HBV DNA \\\u003C 10³ IU\u002Fml, the patient can be enrolled. If a patient is HCV antibody positive, HCV RNA is detected by PCR technology, and a positive result meets the exclusion criterion;\n10. Need for continuous treatment with strong or moderate CYP3A inhibitors or CYP3A inducers;\n11. nability to swallow capsules or presence of diseases that significantly affect gastrointestinal function, such as malabsorption syndrome, bariatric surgery, inflammatory bowel disease, or partial or complete intestinal obstruction;\n12. Other concurrent and uncontrolled medical conditions that the investigator deems will affect the patient's participation in the study.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","To evaluate orelabrutinib in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) as first-line treatment for patients with intermediate- to high-risk diffuse large B-cell lymphoma (DLBCL).",[27,28,29],"DLBCL - Diffuse Large B Cell Lymphoma","Intermediate-High Risk","First-Line","RECRUITING","2026-08-20",{"date":33,"type":34},"2026-08-21","ACTUAL",{"date":36,"type":21},"2026-08-30",{"date":38,"type":21},"2028-12-31",{"name":40,"class":41},"The First Affiliated Hospital of Xiamen University","OTHER",2,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100636833","phase-3-a-study-to-evaluate-the-safety-and-efficacy-of-sctb35-in-combination-with-gemcitabine-and-oxaliplatin-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-100636833","NCT07570823","A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n* Age 18-80 years old\n* Histologically confirmed diffuse large B-cell lymphoma according to WHO 2022 criteria\n* Relapsed or refractory (R\u002FR) disease following at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy\n* Participants who have failed after one prior line of therapy are not candidates for high-dose chemotherapy followed by autologous stem cell transplant (ASCT)\n* Presence of measurable or evaluable disease at baseline ECOG PS 0-2\n* ECOG PS 0-2\n* Adequate organ function and bone marrow function\n* Expected survival ≥ 3 months\n\nExclusion Criteria:\n\n* Prior treatment with antibodies targeting both CD20 and CD3\n* Contraindication to rituximab, gemcitabine or oxaliplatin, or prior treatment with an anti-CD20 antibody in combination with the GemOx regimen\n* Peripheral neuropathy assessed to be Grade \\>1 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v6.0 at enrollment\n* Known central nervous system (CNS) involvement by lymphoma\n* Known any major episode of active infection requiring treatment with systemic antibiotics within 2 weeks\n* Treatment with chimeric antigen receptor T-cell (CAR-T) therapy within 100 days prior to first SCTB35 administration\n* Autologous HSCT within 100 days prior to first SCTB35 administration, or any prior allogeneic HSCT or solid organ transplantation\n* Major surgery within 4 weeks prior to first SCTB35 administration\n* Chemotherapy and other non-investigational antineoplastic agents (except CD20 mAbs) within 4 weeks or 5 half-lives (whichever is shorter) prior to first SCTB35 administration\n* Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study","80 Years",{"count":52,"type":21},101,[54],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Gemcitabine and Oxaliplatin vs Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.",[27],"2026-08-11",{"date":59,"type":34},"2026-08-13",{"date":61,"type":34},"2026-06-04",{"date":63,"type":21},"2029-04",{"name":65,"class":66},"Sinocelltech Ltd.","INDUSTRY",1,{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":67},"100649797","modified-dhap-versus-standard-dhap-in-relapsedrefractory-diffused-large-b-cell-lymphoma-100649797","NCT07739654","Modified DHAP Versus Standard DHAP in Relapsed\u002FRefractory Diffused Large B-cell Lymphoma.","Comparison of Effectiveness and Toxicities of Modified DHAP Protocol With Standard DHAP Protocol in Patients With Relapsed\u002FRefractory Diffused Large B-cell Lymphoma.","MOD-DHAP","Inclusion Criteria:\n\n* Histologically confirmed relapsed or refractory DLBCL\n* Adults ≥ 18 years\n* At least one prior line of therapy for lymphoma\n* ECOG performance status 0-2\n* Ability to provide informed consent and comply with study requirements\n* Adequate organ function:\n* Hematologic: ANC ≥ 1,000 cells\u002Fmm³, Platelets ≥ 75,000 cells\u002Fmm³\n* Renal: Serum creatinine ≤ 1.5 × ULN\n* Hepatic: Total bilirubin ≤ 1.5 × ULN, AST\u002FALT ≤ 2.5 × ULN (if no liver metastases)\n\nExclusion Criteria:\n\n* History of other malignancies within last 5 years (except non-melanoma skin cancer or localized prostate cancer)\n* Pregnant or breastfeeding women\n* Significant uncontrolled medical conditions (e.g., cardiovascular disease, uncontrolled diabetes)\n* Receipt of investigational agents within 30 days prior to enrollment\n* Known severe allergic reactions to DHAP components (dexamethasone, cytarabine, cisplatin)\n* Concurrent anti-cancer treatments (chemotherapy, radiotherapy) during study period",{"count":77,"type":21},74,[54],"This Phase III randomized controlled trial evaluates the effectiveness and toxicity profile of a modified DHAP regimen compared to the standard DHAP regimen in adult patients with relapsed\u002Frefractory diffuse large B-cell lymphoma (DLBCL). The DHAP regimen (cisplatin, cytarabine, dexamethasone) is widely used as salvage therapy but is associated with significant toxicities, including renal dysfunction and severe myelosuppression. The modified DHAP protocol fractionates cisplatin and cytarabine administration to reduce nephrotoxicity, improve tolerability, and potentially allow outpatient treatment.\n\nA total of 74 patients will be randomized (37 per arm) to receive either the modified or standard DHAP regimen. The primary endpoint is overall response rate (ORR) assessed by RECIL 2017 criteria. Secondary endpoints include progression-free survival (PFS), toxicity incidence and severity graded by CTCAE, and quality of life measured by EORTC QLQ-C30.\n\nThe study anticipates that the modified DHAP regimen will demonstrate comparable or superior efficacy with reduced severe toxicities, shorter hospital stays, and improved patient satisfaction. Findings may support transitioning DHAP into outpatient administration, optimizing healthcare resource utilization in Pakistan.",[27],[82,83,84],"DLBCL","DHAP","B cell Lymphoma","2026-08-06",{"date":87,"type":34},"2026-08-10",{"date":89,"type":34},"2026-03-18",{"date":91,"type":21},"2027-10-20",{"name":93,"class":41},"King Edward Medical University",{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":114,"leadSponsor":116,"locationsCount":67},"100650312","phase-2-pirtobrutinibsonrotoclaxps-regimen-in-the-treatment-of-b-cell-lymphoma-100650312","NCT07744750","Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma","A Prospective, Phase II, Multicenter Clinical Study of Pirtobrutinib Combined With Sonrotoclax Regimen in the Treatment of B-Cell Lymphoma","Inclusion Criteria:\n\n* Cohort 1: Histologically transformed DLBCL\n\n  1. Histopathologically confirmed histologically transformed DLBCL, including transformation from indolent lymphomas such as CLL, WM, FL, and MZL.\n  2. Whole-body PET\u002FCT performed within 28 days prior to study enrollment demonstrating at least one measurable lesion in two perpendicular dimensions (longest diameter \\>15 mm for nodal lesions, or longest diameter \\>10 mm for extranodal lesions).\n  3. Except patients with Richter transformation, patients transformed from MZL, FL, WM, etc., must have received at least one line of systemic anti-lymphoma therapy either during the indolent phase or after transformation.\n\nCohort 2: Relapsed\u002Frefractory CLL\u002FSLL\n\n1. Histopathologically confirmed relapsed\u002Frefractory CLL\u002FSLL.\n2. Disease relapse or refractoriness after at least one line of systemic anti-lymphoma therapy, which may include a BTK inhibitor.\n\nCohort 3: Relapsed\u002Frefractory MZL\n\n1.Histopathologically confirmed relapsed\u002Frefractory MZL. 2.Received systemic therapy containing an anti-CD20 monoclonal antibody or a BTK inhibitor.\n\n3.Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2. 4.Age ≥ 18 years. 5.Adequate organ and bone marrow function defined as follows:\n\n1. Hematologic function (assessed within 7 days prior to Cycle 1 Day 1 \\[C1D1\\]): a. Absolute neutrophil count (ANC) ≥ 0.5 × 10⁹\u002FL. Patients with values below this threshold may be eligible if there is documented bone marrow involvement impairing hematopoiesis. b. Platelet count ≥ 50 × 10⁹\u002FL without transfusion support. Patients with values below this threshold may be eligible if there is documented bone marrow infiltration impairing hematopoiesis. c. If transfusions are administered to treat thrombocytopenia or anemia, the patient must demonstrate a response to transfusion support.\n2. Coagulation function: Activated partial thromboplastin time (aPTT), prothrombin time (PT), or international normalized ratio (INR) ≤ 1.5 × upper limit of normal (ULN).\n3. Hepatic function: Serum total bilirubin (TBIL) ≤ 1.5 × ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN.\n4. Renal function: Serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance (CCr) ≥ 30 mL\u002Fmin.\n5. Cardiac function: New York Heart Association (NYHA) functional class less than Class III; ejection fraction ≥ 50% on echocardiogram.\n\n6.Estimated survival \\> 3 months. 7.Able to provide written informed consent and comply with protocol-specified study visits and procedures.\n\n8.Female subjects of childbearing potential, or male subjects whose female partners are of childbearing potential, must utilize effective contraceptive measures throughout the treatment period and for 90 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n1. DLBCL with central nervous system or leptomeningeal involvement;\n2. Prior treatment with a non-covalent BTK inhibitor;\n3. Prior treatment with immune checkpoint inhibitors;\n4. Contraindication or hypersensitivity to any drug in the combination treatment regimen;\n5. Concurrent other malignancies requiring treatment or intervention;\n6. Major surgery within 4 weeks prior to treatment (excluding vascular access catheterization or biopsy);\n7. Any life-threatening disease, medical condition or organ dysfunction that, in the Investigator's opinion, may compromise patient safety or compliance with study procedures;\n8. Uncontrolled clinical cardiac signs or diseases, including: i. Heart failure of NYHA Class ≥ II ii. Unstable angina pectoris iii. Myocardial infarction within the past 12 months iv. Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n9. Patients with active bleeding;\n10. Active and uncontrolled systemic bacterial, viral, fungal or parasitic infection (excluding fungal nail infection), or other clinically significant active disease process rendering the patient unsuitable for trial participation as judged by the Investigator.\n11. Patients with active chronic hepatitis B or active hepatitis C. Patients positive for Hepatitis B surface antigen (HBsAg) and\u002For Hepatitis B core antibody (HBcAb), or Hepatitis C virus (HCV) antibody at screening must undergo further Hepatitis B virus (HBV) DNA testing (≤2500 copies\u002FmL or ≤500 IU\u002FmL) to rule out active hepatitis B or active hepatitis C requiring treatment before enrollment. Nevertheless, eligible patients with positive HBsAg and\u002For HBcAb must receive anti-hepatitis B antiviral therapy.\n12. Patients infected with Human Immunodeficiency Virus (HIV) and\u002For patients with acquired immunodeficiency syndrome (AIDS);\n13. Inability to swallow tablets, presence of malabsorption syndrome, or any other gastrointestinal disease or dysfunction that may affect absorption of the study drug;\n14. Pregnant or lactating women;\n15. Patients with psychiatric disorders or those unable to provide informed consent;\n16. Patients deemed unsuitable for participation in this study by the Investigator.",{"count":102,"type":21},40,[104],"PHASE2","This prospective, open-label, Phase II clinical trial evaluates the efficacy and safety of pirtobrutinib combined with sotoclax across three distinct B-cell lymphoma cohorts: histologically transformed diffuse large B-cell lymphoma (DLBCL), relapsed\u002Frefractory chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL), and relapsed\u002Frefractory marginal zone lymphoma (MZL). Dosing regimen ：pirtobrutinib 200 mg orally once daily plus sotoclax with a 4-week dose escalation schedule (1, 2, 5, 10, 20, 40, 80, 160 mg\u002Fday, then 320 mg\u002Fday on days 1-28, starting Cycle 2) administered orally. Cohorts 1 and 2 additionally incorporate obinutuzumab 1000 mg intravenously on Cycle 1 days 1, 8, and 15, followed by days 1 of Cycles 2 through 6, with a maximum of six cycles. Each treatment cycle spans 28 days.\n\nFor Cohort 1 (RT DLBCL), the primary objective centers on early response assessment following three cycles of the PSO regimen (pirtobrutinib-sotoclax-obinutuzumab), with PET\u002FCT evaluation serving as the critical decision point. Patients demonstrating progressive disease or stable disease discontinue study treatment, while those achieving complete or partial response may proceed to investigator-selected bridging therapies including bispecific antibodies, CAR-T cell therapy, or hematopoietic stem cell transplantation, or alternatively continue PSO combination therapy. Obinutuzumab is capped at six cycles, whereas pirtobrutinib and sotoclax may continue for up to 25 cycles. Comprehensive biomarker strategies include ctDNA analysis from peripheral blood at baseline and after Cycle 1 (following full-dose sotoclax exposure), with serial assessments at Cycles 3, 7, 14, and every six cycles during Year 2 for patients continuing PSO beyond Cycle 3. Patients with measurable baseline tumor cells in peripheral blood or bone marrow undergo flow cytometry-based MRD detection at 10-⁴ sensitivity at corresponding timepoints. T-cell subset and functional analyses are performed at baseline, Cycle 3, and every three cycles thereafter to characterize immune dynamics during treatment.\n\nCohort 2 (relapsed\u002Frefractory CLL\u002FSLL) follows a continuous treatment paradigm without an early stopping rule, with efficacy assessment after fourteen cycles. Patients achieving complete remission with MRD negativity at 10-⁴ may elect treatment discontinuation. Sotoclax is administered for a maximum of twenty-four cycles, with pirtobrutinib maintenance for patients failing to achieve MRD-negative complete remission. The biomarker program incorporates both flow cytometry MRD at 10-⁴ and next-generation sequencing MRD at 10-⁶ sensitivity, providing unprecedented depth of residual disease characterization. Sampling occurs at baseline, Cycle 1, Cycle 3, Cycle 7, Cycle 14, and every six cycles in Year 2.\n\nCohort 3 (relapsed\u002Frefractory MZL) mirrors the CLL\u002FSLL treatment structure but omits obinutuzumab, testing the doublet of pirtobrutinib plus sotoclax. The fourteen-cycle efficacy assessment and MRD-guided stopping rule apply identically, with sotoclax limited to twenty-four cycles and pirtobrutinib maintenance for non-responders. ctDNA surveillance occurs at baseline, Cycle 3, Cycle 7, Cycle 14, and every six cycles in Year 2, complemented by serial T-cell immunophenotyping.",[27,107,108,109],"Richter Transformation","CLL \u002F SLL","MZL","NOT_YET_RECRUITING","2026-08-04",{"date":85,"type":34},{"date":36,"type":21},{"date":115,"type":21},"2029-08-31",{"name":117,"class":41},"Changzhou No.2 People's Hospital",{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":67},"100650276","phase-2-pirtobrutinib--r-chop-for-untreated-non-gcb-dlbcl-100650276","NCT07744737","Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL","A Prospective, Multicenter Clinical Study of Pirtobrutinib Combined With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) for the Treatment of Previously Untreated Non-GCB DLBCL","Inclusion Criteria:\n\n1. Histopathologically confirmed non-GCB diffuse large B-cell lymphoma (DLBCL) (per the 2016 WHO diagnostic criteria);\n2. Whole-body PET\u002FCT performed within 28 days prior to study enrollment demonstrating at least one measurable lesion (per the 2014 Lugano Criteria);\n3. Age 18-80 years, with estimated survival \\> 3 months;\n4. No prior anti-lymphoma treatment;\n5. Able to provide written informed consent and comply with scheduled study visits and required procedures specified in the protocol;\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;\n7. Adequate organ and bone marrow function, defined as follows: Hematology: Absolute neutrophil count (ANC) ≥ 0.5 × 10⁹\u002FL; platelet count (PLT) ≥ 50 × 10⁹\u002FL; hemoglobin (HGB) ≥ 8.0 g\u002FdL. No administration of granulocyte growth factors, platelet transfusions or red blood cell transfusions within 7 days before testing. Liver function: Total serum bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN. Renal function: Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance (CCr) ≥ 50 mL\u002Fmin. Cardiac function: New York Heart Association (NYHA) functional class \\\u003C III; left ventricular ejection fraction (LVEF) ≥ 50% on echocardiography. Coagulation function: International normalized ratio (INR) ≤ 1.5 × ULN; activated partial thromboplastin time (APTT) ≤ upper limit of normal +10 s; prothrombin time (PT) ≤ upper limit of normal +3 s. Thyroid function: Baseline thyroid-stimulating hormone (TSH) within normal range, or abnormal baseline TSH with normal T3\u002FT4 and absence of related clinical symptoms.\n8. Female subjects of childbearing potential, or male subjects whose sexual partners are females of childbearing potential, must adopt effective contraceptive measures throughout the treatment period and for 90 days after the last treatment administration.\n\nExclusion Criteria:\n\n1. Central nervous system involvement;\n2. History of hypersensitivity to the study drug, similar agents, or excipients;\n3. Concurrent other malignancies requiring treatment or intervention;\n4. Major surgical procedure performed within 4 weeks prior to treatment (excluding vascular access catheterization or biopsy);\n5. Any life-threatening disease, medical condition, or organ dysfunction that, in the Investigator's opinion, may compromise patient safety or adherence to study procedures;\n6. Poorly controlled cardiac symptoms or diseases, including: i. Heart failure of NYHA Class ≥ II; ii. Unstable angina pectoris; iii. Myocardial infarction within the past 12 months; iv. Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n7. Patients with active bleeding;\n8. Uncontrolled active systemic bacterial, viral, fungal or parasitic infection (excluding fungal nail infection), or other clinically significant active disease process that renders the patient unsuitable for participation in this trial as judged by the Investigator.\n9. Known history of human immunodeficiency virus (HIV) infection and\u002For acquired immunodeficiency syndrome (AIDS).\n10. Patients with active chronic hepatitis B or active hepatitis C are excluded.Patients positive for hepatitis B surface antigen, hepatitis B core antibody or hepatitis C virus antibody during screening must undergo further testing for HBV-DNA and HCV-RNA. Patients with stable hepatitis B after antiviral therapy (HBV-DNA \\\u003C 2500 copies\u002FmL or 500 IU\u002FmL) and cured hepatitis C patients (HCV-RNA below the lower limit of detection) are eligible for enrollment.\n11. Confirmed prior history of neurological or psychiatric disorders, including epilepsy or dementia;\n12. Pregnant or lactating women;\n13. Received any other investigational product within 1 month prior to the first dose;\n14. Other conditions that, in the Investigator's judgment, may interfere with the evaluation of efficacy or safety of the study treatment.",{"count":126,"type":21},34,[104],"To evaluate the efficacy and safety of pirtobrutinib combined with R-CHOP in patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL)",[27,130,131],"R-CHOP Chemotherapy","Pirtobrutinib",{"date":85,"type":34},{"date":134,"type":21},"2026-07-30",{"date":136,"type":21},"2029-04-30",{"name":117,"class":41},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":67},"100650180","phase-2-pirtobrutinibpola-r-chp-for-newly-diagnosed-non-gcb-dlbcl-100650180","NCT07744724","Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL","A Prospective, Multicenter Clinical Study of Pirtobrutinib Combined With Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Newly Diagnosed Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL)","Inclusion Criteria:\n\n1. Histologically confirmed Non-GCB DLBCL (per 2016 WHO diagnostic criteria);\n2. Whole-body PET\u002FCT performed within 28 days prior to study enrollment demonstrating at least one measurable lesion (per 2014 Lugano criteria);\n3. Age 18-65 years, with expected survival \\>3 months;\n4. No prior anti-lymphoma treatment;\n5. Signed written informed consent and ability to comply with protocol-required visits and procedures;\n6. ECOG performance status 0-2;\n7. Adequate organ and bone marrow function, defined as follows:\n\n   * Hematology: Absolute neutrophil count (ANC) ≥1×10⁹\u002FL, platelet count (PLT) ≥50×10⁹\u002FL, hemoglobin (HGB) ≥8.0 g\u002FdL; no granulocyte colony-stimulating factor, platelet transfusion, or red blood cell transfusion within 7 days prior to testing;\n   * Hepatic function: Total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN;\n   * Renal function: Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCR) ≥50 mL\u002Fmin;\n   * Cardiac function: NYHA Class III or below; left ventricular ejection fraction ≥50% by echocardiography;\n   * Coagulation: International normalized ratio (INR) ≤1.5×ULN, activated partial thromboplastin time (APTT) ≤ULN +10s, and prothrombin time (PT) ≤ULN +3s;\n8. Women of childbearing potential or male subjects with partners of childbearing potential must use effective contraception throughout the treatment period and for 90 days after the last dose.\n\nExclusion Criteria:\n\n1. Central nervous system involvement;\n2. History of hypersensitivity to the study drug, drugs of the same class, or excipients;\n3. Concurrent malignancy requiring treatment or intervention;\n4. Major surgery within 4 weeks prior to treatment (excluding vascular access catheter placement or biopsy);\n5. Presence of any life-threatening disease, medical condition, or organ system dysfunction that, in the investigator's opinion, may affect patient safety or compliance with study procedures;\n6. Uncontrolled cardiac symptoms or disease, including: i. NYHA Class II or higher heart failure; ii. Unstable angina; iii. Myocardial infarction within 1 year; iv. Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n7. Active bleeding;\n8. Active, uncontrolled systemic bacterial, viral, fungal, or parasitic infection (excluding onychomycosis), or other clinically significant active disease process that, in the investigator's opinion, renders the patient unsuitable for clinical trial participation;\n9. Known history of human immunodeficiency virus (HIV) infection and\u002For acquired immunodeficiency syndrome;\n10. Exclusion of patients with active chronic hepatitis B or active hepatitis C. Patients with positive hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C virus antibody at screening must undergo further HBV-DNA and HCV-RNA testing. Patients with stable hepatitis B (HBV-DNA \\\u003C2500 copies\u002FmL or 500 IU\u002FmL) on antiviral therapy and cured hepatitis C patients (below the limit of detection) may be enrolled;\n11. Definitive history of neurological or psychiatric disorder, including epilepsy or dementia;\n12. Pregnant or lactating women;\n13. Receipt of other investigational agents within 1 month prior to first dose;\n14. Any other factors that, in the investigator's opinion, may affect the evaluation of efficacy or safety in this study.","65 Years",{"count":147,"type":21},48,[104],"This is a single-arm, open-label, multicenter clinical study evaluating the efficacy and safety of pirtobrutinib combined with Pola-R-CHP in previously untreated Non-GCB DLBCL. PET\u002FCT assessment will be performed after 3 cycles of combination therapy. Patients achieving CR\u002FPR will continue treatment for another 3 cycles, while those with PD\u002FSD will be discontinued from the study. Patients achieving CR\u002FPR after 6 cycles of treatment will undergo follow-up with PET\u002FCT or contrast-enhanced CT every 3 months during the first year and every 6 months thereafter, until disease progression, death, withdrawal of informed consent, or study completion, whichever occurs first.",[27,131],{"date":85,"type":34},{"date":153,"type":21},"2026-07-31",{"date":155,"type":21},"2030-07-31",{"name":117,"class":41},{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":67},"100650516","phase-2-hypofractionated-radiotherapy-plus-gm-csf-pomalidomide-and-glofitamab-for-newly-diagnosed-pcns-dlbcl-100650516","NCT07749365","Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL","A Prospective Phase II Clinical Study to Evaluate the Efficacy and Safety of Hypofractionated Radiotherapy Combined With Granulocyte-Macrophage Colony-Stimulating Factor, Pomalidomide and Glofitamab in Patients With Newly Diagnosed Primary Central Nervous System Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n1. Written informed consent must be obtained before any study-related procedures.\n2. Age ≥18 years, regardless of sex, with an expected survival time \\>3 months.\n3. Histologically confirmed diffuse large B-cell lymphoma (DLBCL).\n4. Newly diagnosed patients with primary central nervous system diffuse large B-cell lymphoma (PCNSL).\n5. No previous treatment with bispecific antibodies.\n6. B-cell non-Hodgkin lymphoma with at least one measurable lesion according to RECIST 1.1 criteria, or detectable abnormal monoclonal B cells by cerebrospinal fluid (CSF) flow cytometry.\n7. Adequate organ function meeting the following laboratory criteria:\n\n   * Total bilirubin ≤1.5 × upper limit of normal (ULN);\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN;\n   * Serum creatinine ≤1.5 × ULN and creatinine clearance ≥60 mL\u002Fmin (calculated using the Cockcroft-Gault formula);\n   * Adequate coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5 × ULN.\n8. Women of childbearing potential must have a negative urine or serum pregnancy test within 3 days before the first dose of study treatment (Cycle 1 Day 1). If urine pregnancy testing cannot confirm a negative result, a serum pregnancy test is required. Women of non-childbearing potential are defined as those who are postmenopausal for ≥1 year or have undergone surgical sterilization or hysterectomy.\n9. All participants with reproductive potential (male or female) must use highly effective contraception with a failure rate \\\u003C1% per year during treatment and for 120 days after the last dose of study drug (or 180 days after the last dose of chemotherapy).\n\nExclusion Criteria:\n\n1. Loss of CD20 expression in B-cell non-Hodgkin lymphoma.\n2. Active acute or chronic hepatitis B or hepatitis C infection, including:\n\n   * HBV DNA \\>2,000 IU\u002FmL or \\>10⁴ copies\u002FmL without willingness to receive regular antiviral therapy;\n   * HCV RNA \\>10³ copies\u002FmL;\n   * Concurrent positivity for HBsAg and anti-HCV antibody.\n3. Receipt of anti-hematologic malignancy therapy within 2 weeks or within 5 pharmacokinetic half-lives before treatment initiation, whichever is longer.\n4. Inadequate bone marrow reserve, defined as platelet count \\\u003C30 ×10⁹\u002FL or absolute neutrophil count \\\u003C1.0 ×10⁹\u002FL.\n5. Clinically significant pulmonary diseases, including:\n\n   * Chronic obstructive pulmonary disease (COPD) with FEV1 \\\u003C50% of predicted value;\n   * Moderate or severe persistent asthma within the past 2 years or uncontrolled asthma of any severity.\n6. Uncontrolled hypertension despite optimal medical management (systolic blood pressure \\>150 mmHg or diastolic blood pressure \\>90 mmHg), history of hypertensive crisis, or hypertensive encephalopathy.\n7. Symptomatic congestive heart failure (NYHA class II-IV), symptomatic or poorly controlled arrhythmias, congenital long QT syndrome, or corrected QT interval (QTc) \\>500 ms (Fridericia correction).\n8. Receipt of hypofractionated radiotherapy within 4 weeks before the first treatment. Patients receiving radiotherapy \\>4 weeks before enrollment must have no ongoing radiation-related toxicities, no requirement for corticosteroids, and no evidence of radiation pneumonitis, hepatitis, enteritis, or other radiation-related complications.\n9. Difficulty swallowing oral medications.\n10. History or presence of pulmonary fibrosis, interstitial lung disease, pneumoconiosis, drug-induced pneumonitis, or severe pulmonary dysfunction.\n11. HIV infection (positive HIV-1\u002F2 antibody) or known syphilis infection.\n12. Presence of unhealed wounds, fractures, gastric or duodenal ulcers, persistent positive fecal occult blood test, ulcerative colitis, or other conditions associated with risk of gastrointestinal bleeding or perforation as determined by the investigator.\n13. Active or uncontrolled severe infection, including severe infection requiring hospitalization due to infection, bacteremia, or severe pneumonia within 4 weeks before the first dose.\n14. Major surgery or significant traumatic injury within 4 weeks before the first dose.\n15. Use of traditional Chinese medicine with antitumor indications within 2 weeks before the first dose.\n16. Known hypersensitivity to any component of bispecific antibodies or GM-CSF preparations.\n17. Receipt of treatment in another clinical trial within 4 weeks before the first dose.\n18. Pregnant or breastfeeding women.\n19. Active autoimmune disease or history of autoimmune disease, including but not limited to autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, and nephritis. Patients requiring medical intervention with bronchodilators for asthma are excluded. The following conditions are permitted: vitiligo, psoriasis, alopecia, or controlled type I diabetes not requiring systemic treatment, and hypothyroidism controlled with hormone replacement therapy.\n20. Any other acute or chronic disease, psychiatric condition, or abnormal laboratory finding that may:\n\n    * Increase the risk associated with study participation or administration of study treatment;\n    * Interfere with interpretation of study results;\n    * Render the patient unsuitable for participation according to the investigator's judgment.",{"count":165,"type":21},53,[104],"This prospective study was conducted to evaluate the efficacy and safety of hypofractionated radiotherapy combined with granulocyte-macrophage colony-stimulating factor, pomalidomide and glofitamab in patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma.",[27,169],"PCNSL (Primary CNS Lymphoma)","2026-08-02",{"date":85,"type":34},{"date":173,"type":21},"2026-07-25",{"date":175,"type":21},"2029-12-31",{"name":40,"class":41},{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":203},"100602318","phase-1-this-is-a-phase-1-study-to-evaluate-the-safety-of-ltz-301-in-patients-with-non-hodgkin-lymphoma-100602318","NCT07121946","This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma","A Phase 1, Open-label, Multicenter Study of LTZ-301 in Subjects With Relapsed\u002FRefractory Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Relapsed or refractory to at least 2 prior systemic treatment regimens\n* At least 1 bi-dimensionally measurable lesion (≥ 1.5 cm) in longest dimension\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Adequate bone marrow, cardiac, pulmonary, renal, and hepatic function\n\nExclusion Criteria:\n\n* CLL, or Richters transformation\n* Prior solid organ transplant\n* Prior allogeneic stem cell transplant\n* ASCT within 100 days prior to the first LTZ-301 administration\n* Prior CAR-T within 60 days prior to the first LTZ-301 administration\n* Current central nervous system (CNS) lymphoma\n* Known history of human immunodeficiency virus (HIV) seropositivity\n* Active autoimmune disease\n* History of clinically significant cardiovascular disease\n* symptomatic deep vein thrombosis (DVT) within 3 months of enrollment\n* History of other malignancy within 3 years prior to screening",{"count":185,"type":21},42,[187],"PHASE1","This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma",[190,27,191,192,193],"Non-Hodgkin Lymphoma Refractory\u002F Relapsed","Mantle Cell Lymphoma (MCL)","Follicular Lymphoma ( FL)","Marginal Zone Lymphoma (MZL)","2026-07-22",{"date":196,"type":34},"2026-07-24",{"date":198,"type":34},"2026-01-29",{"date":200,"type":21},"2028-02",{"name":202,"class":66},"LTZ Therapeutics, Inc.",6,{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":224,"locationsCount":67},"100645362","phase-2-orelabrutinib-combined-with-standard-immunochemotherapy-with-or-without-autologous-hematopoietic-stem-cell-transplantation-auto-hsct-for-newly-diagnosed-diffuse-large-b-cell-lymphoma-dlbcl-100645362","NCT07680933","Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)","A Prospective, Phase II Clinical Study Protocol of Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)","Inclusion Criteria:\n\n* Signed informed consent;\n\n  * Age 18-80 years at the time of signing informed consent, and willingness to comply with the study protocol procedures;\n\n    * Pathologically confirmed CD20-positive DLBCL;\n\n      ④ IPI score of 2-5;\n\n      ⑤ ECOG performance status of 0-2;\n\n      ⑥ Life expectancy ≥12 months;\n\n      ⑦ Left ventricular ejection fraction (LVEF) ≥50% as assessed by multigated acquisition (MUGA) scan or echocardiography (ECHO);\n      * Adequate hematologic function (unless due to underlying disease, e.g., extensive bone marrow involvement, or hypersplenism secondary to splenic involvement attributed to DLBCL as determined by the investigator; transfusion of blood products is permitted), defined as follows:\n\n        1. Hemoglobin ≥90 g\u002FL within 7 days prior to enrollment without packed red blood cell transfusion;\n        2. Absolute neutrophil count (ANC) ≥1.0 × 10⁹\u002FL;\n        3. Platelet count ≥75 × 10⁹\u002FL.\n\n           ⑨ Adequate organ function.\n\n           Exclusion Criteria:\n* Presence of uncontrolled cardiovascular or cerebrovascular disease, coagulation disorders, autoimmune diseases, severe infectious diseases, etc.;\n\n  * Abnormal laboratory values at screening (unless attributable to lymphoma):\n\n    1. Coagulation function: INR \\> 1.5× the upper limit of normal (ULN); PT and APTT \\> 1.5× ULN;\n    2. Liver function: ALT or AST \\> 2× ULN; ALP and bilirubin \\> 1.5× ULN;\n    3. Renal function: Creatinine \\> 1.5× ULN; creatinine clearance \\\u003C 60 mL\u002Fmin (estimated by the Cockcroft-Gault formula);\n\n       ③ HIV-infected patients;\n\n       ④ For HBsAg-positive patients, HBV DNA must be negative prior to enrollment. In addition, if a patient is HBsAg-negative but HBcAb-positive (regardless of HBsAb status), HBV DNA testing is still required. If the result is positive, antiviral therapy is needed, and HBV DNA must be negative prior to enrollment;\n\n       ⑤ Requiring continuous treatment with strong or moderate CYP3A inhibitors or CYP3A inducers. Patients who have taken strong or moderate CYP3A inhibitors or CYP3A inducers within 7 days prior to the first dose of study drug (or have not completed at least 5 half-lives since the last dose) are not eligible for enrollment;\n       * Inability to swallow capsules or presence of gastrointestinal conditions that significantly affect gastrointestinal function, such as malabsorption syndrome, gastric or small bowel resection, symptomatic inflammatory bowel disease, or partial or complete intestinal obstruction;\n\n         * Other concurrent and uncontrolled medical conditions that, in the investigator's opinion, may affect the patient's participation in the study, including patients with psychiatric disorders or other known or suspected inability to fully comply with the study protocol.",{"count":20,"type":21},[104],"This study is a prospective, open-label, multicenter study in previously untreated participants with CD20-positive DLBCL. Orelabrutinib combined with standard immunochemotherapy with or without autologous hematopoietic stem cell transplantation (auto-HSCT) for newly diagnosed diffuse large B-cell lymphoma (DLBCL). The primary objective is to explore the 1-year progression-free survival (PFS) of orelabrutinib combined with standard immunochemotherapy with or without auto-HSCT in newly diagnosed DLBCL.",[27],[216,82,217],"Orelabrutinib","auto-HSCT","2026-06-30",{"date":220,"type":34},"2026-07-02",{"date":222,"type":34},"2026-03-01",{"date":38,"type":21},{"name":225,"class":41},"The Affiliated Hospital of Xuzhou Medical University",{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":67},"100645142","phase-2-orelabrutinib-combined-with-induction-therapy-followed-by-sequential-monotherapy-maintenance-in-mcd-subtype-diffuse-large-b-cell-lymphoma-100645142","NCT07677813","Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma","Efficacy and Safety of Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma: a Single-center, Single-arm, Prospective Study","Inclusion Criteria:\n\n* Patients of any gender, aged ≥18 years;\n* Pathologically, NGS, and imaging confirmed diagnosis of MCD subtype DLBCL (including IP-LBCLs);\n* No prior treatment history;\n* Serum creatinine ≤2 times the upper limit of normal or eGFR ≥40 ml\u002Fmin;\n* Bilirubin \\\u003C1.5 times the upper limit of normal;\n* Understand and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or lactating women and women of childbearing age who are unwilling to use contraception;\n* Patients with a history of stroke or bleeding within the past 6 months;\n* Patients requiring treatment with strong CYP3A inhibitors;\n* Patients with comorbid autoimmune deficiency diseases or active hepatitis virus infection;\n* Patients with a history of organ transplantation;\n* Patients with a history of or concurrent other malignant tumors.",{"count":234,"type":21},66,[104],"This is a single-center, single-arm, prospective study aimed at evaluating the efficacy and safety of orelabrutinib combined with an induction regimen followed by monotherapy maintenance in patients with MCD subtype diffuse large B-cell lymphoma (DLBCL). The primary endpoint is the 2-year progression-free survival (PFS) rate; secondary endpoints include overall response rate (ORR), complete response rate (CRR), overall survival (OS), and treatment-related adverse events (TRAEs). The study plans to enroll 66 patients.",[27],[239,82,240,241,242],"orelabrutinib","chemotherapy","Maintenance therapy","MCD subtype","2026-06-25",{"date":245,"type":34},"2026-07-01",{"date":247,"type":21},"2026-06-16",{"date":249,"type":21},"2031-12-31",{"name":251,"class":41},"Ou Bai, MD\u002FPHD",{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":271,"locationsCount":42},"100430794","phase-2-car-t-followed-by-bispecific-antibodies-100430794","NCT04889716","CAR-T Followed by Bispecific Antibodies","Phase II Study of Dual Targeting of CD19 and CD20 Antigens Using Sequential CD19-directed CAR-T Cells Followed by Mosunetuzumab or Glofitamab in Relapsed or Refractory Diffuse Large B-cell or Transformed Follicular Lymphomas","Inclusion Criteria:\n\n* Life expectancy of at least 12 weeks\n* History of relapsed or refractory large B-cell lymphoma (including transformed follicular lymphoma, and follicular lymphoma Grade 3B) who have relapsed after or failed to respond to at least one prior standard systemic treatment regimen that contains an anthracycline and at least one containing an anti-CD20-directed therapy and for whom there is no available therapy expected to improve survival (e.g., standard chemotherapy, autologous or allogeneic stem cell transplant).\n* PET\u002FCT scan (preferred), diagnostic CT scan, or MRI prior to CAR-T cell therapy, with at least one bi-dimensionally measurable lesion (≥ 1.5 cm for nodal lesion or ≥ 1cm for extra-nodal lesions in largest dimension by low-dose computerized tomography \\[CT\\] scan with FDG-uptake ≥ liver); this imaging must have been obtained within 56 days of receiving CAR T cell therapy.\n* PET\u002FCT scan (preferred), diagnostic CT scan, or MRI with at least one bi-dimensionally measurable lesion (≥ 1.5 cm for nodal lesion or ≥ 1cm for extra-nodal lesions in largest dimension by low-dose computerized tomography \\[CT\\] scan with FDG-uptake ≥ liver); this imaging documenting measurable disease must be obtained at least day +28 after CAR T cell infusion and prior to cycle 1 day 1.\n* Be at least 30 days after CAR T-cell infusion at time of study enrollment.\n* Adequate laboratory studies,\n* Ability and willingness to take proper contraceptive precautions\n\nExclusion Criteria:\n\n* Had \\> Grade 3 cytokine release syndrome (CRS) by ASTCT criteria after CAR-T therapy or who have unresolved CRS after CAR-T therapy\n* Had ≥ grade 2 neurologic toxicity by ASTCT criteria after CAR-T therapy or who have active neurologic toxicity after CAR-T therapy\n* Inability to comply with protocol-mandated hospitalization and activities restrictions in the investigators' decision\n* Pregnant or lactating, or intending to become pregnant during the study or within 3 months after the last dose of bispecific antibody or 18 months of obinutuzumab, whichever comes later\n* Prior solid organ transplantation\n* Active systemic autoimmune disease or other disease requiring chronic immunosuppressive therapy\n* History of confirmed progressive multifocal leukoencephalopathy (PML)\n* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)\n* History of other malignancy that could affect compliance with the protocol or interpretation of results\n* Significant cardiovascular disease such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina)\n* Significant active pulmonary disease (e.g., bronchospasm and\u002For obstructive pulmonary disease) requiring oxygen or corticosteroid use.\n* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major documented infection requiring treatment with IV antibiotics or hospitalization within 2 weeks prior to first mosunetuzumab or glofitamab administration. Empiric or prophylactic antibiotics administered during neutropenia or neutropenic fever without microbiologic evidence of infection do not exclude patients.\n* Recent major surgery within 4 weeks prior to first mosunetuzumab or glofitamab administration\n* Active or chronic infection(s) would have increased risks for toxicity if treated with bispecific antibody therapy, thus will be excluded.\n* Administration of a live, attenuated vaccine within 4 weeks before first dose of study treatment or anticipation that such a live attenuated vaccine will be required during the study\n* Received systemic immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) with the exception of corticosteroid treatment \\\u003C 20 mg\u002Fday prednisone or equivalent within 2 weeks prior to first dose of bispecific antibody\n* History of drug or alcohol abuse within 12 months prior to screening in the investigator's judgment\n* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's and\u002For Medical Monitor's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results",{"count":260,"type":21},23,[104],"The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).",[264,27],"Large B-cell Lymphoma","2026-05-21",{"date":267,"type":34},"2026-05-26",{"date":269,"type":34},"2021-11-05",{"date":38,"type":21},{"name":272,"class":41},"Abramson Cancer Center at Penn Medicine",{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":42},"100612155","phase-1-dose-escalation-and-dose-expansion-study-of-mdx2003-in-patients-with-different-types-of-lymphoma-100612155","NCT07249905","Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma","A Phase 1\u002F2 Clinical Study Evaluating MDX2003 in Participants With Relapsed, Progressive, or Refractory B-Cell Malignancies","Inclusion Criteria:\n\n* Participant must be ≥ 18 years of age.\n* Participant has a confirmed diagnosis of large B-cell lymphoma (including DLBCL, high-grade B-cell lymphoma \\[HGBCL\\], primary mediastinal B-cell lymphoma \\[PMBCL\\], etc), FL, MCL, marginal zone lymphoma, transformation of indolent B-cell lymphoma, or lymphoplasmacytic lymphoma, including Waldenstrom macroglobulinemia.\n* Participant has relapsed or progressed on at least 2 prior lines of therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n* All participants must have measurable disease via computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT.\n* Documented CD19 or CD20 positivity of their B-cell neoplasm based on any representative pathology report from the past 3 months.\n* Adequate hematologic, hepatic and renal function.\n* All contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* Capable of giving signed informed consent.\n\nExclusion Criteria:\n\n* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH).\n* Unresolved toxicities from previous anticancer therapy.\n* Primary central nervous system (CNS) lymphoma or known CNS involvement with lymphoma.\n* Active medical condition requiring chronic systemic steroid use (\\>10 mg\u002Fday prednisone or equivalent of \\>140 mg over the last 14 days) or immunosuppressive therapy, within 6 months prior to the first dose of MDX2003.\n* Known positivity with human immunodeficiency virus (HIV), known active hepatitis B or C, or uncontrolled chronic or ongoing infection requiring intravenous treatment.\n* Participant has a history of allogenic tissue or solid organ transplant, with the exception of corneal transplants.\n* Known hypersensitivity to allopurinol or rasburicase.\n* Participant has a seizure disorder requiring therapy at the time of screening (such as steroids or anti-epileptics).\n* Participant is not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions.",{"count":281,"type":21},180,[187,104],"This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma",[285,286,27,287,288,289,290,291],"Lymphoma","Waldenström Macroglobulinemia (WM)","PMBCL","HGBCL","FL Lymphoma","Lymphoplasmacytic Lymphoma","Follicular Lymphoma (FL)","2026-04-30",{"date":294,"type":34},"2026-05-04",{"date":296,"type":34},"2026-04-13",{"date":298,"type":21},"2030-04",{"name":300,"class":66},"ModeX Therapeutics, An OPKO Health Company",{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":17,"minAge":145,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":22,"phases":310,"briefSummary":311,"conditions":312,"keywords":315,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":4},"100635410","phase-2-study-on-the-treatment-of-doubletriple-hit-dlbcl-with-chidamide-and-lisaftoclax-in-combination-with-pola-r-chp-100635410","NCT07552324","Study on the Treatment of Double\u002FTriple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP","Study on the Treatment of Double\u002FTriple-hit Diffuse Large B-cell Lymphoma With Chidamide and Lisaftoclax in Combination With Vepesidil, Rituximab, Cyclophosphamide, Adriamycin, and Prednisone (CL-Pola-R-CHP)","Inclusion Criteria:\n\n* Histopathological diagnosis confirmed as diffuse large B-cell lymphoma, with CD20 positivity;\n* Double or triple hit confirmed by pathology;\n* Age ≥ 65 years old;\n* ECOG performance status score of 0, 1, or 2;\n* No history of malignant tumor; no concurrent occurrence of other tumors;\n* Patients whose life expectancy is at least 6 months, as determined by the researcher;\n* The patient or their legal guardian must provide written informed consent before undergoing any special examinations or procedures in the study.\n* International Prognostic Index (IPI) \\> 1 point.\n\nExclusion Criteria:\n\n* There is a history of other malignant tumors, excluding basal cell carcinoma and cervical carcinoma in situ;\n* Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, etc;\n* Primary central nervous system lymphoma;\n* Left ventricular ejection fraction (LVEF) is less than or equal to 50%;\n* Laboratory test values during screening: (unless caused by lymphoma); A. Neutrophil count \\\u003C1.5\\*10\\^9\u002FL; B. Platelet count \\\u003C75\\*10\\^9\u002FL; C. ALT or AST is more than twice the upper limit of normal, and AKP and bilirubin are more than 1.5 times the upper limit of normal; D. Creatinine level is higher than 1.5 times the upper limit of normal;\n* Other concurrent and uncontrolled medical conditions that the researcher believes will affect the patient's participation in the study.\n* Patients with mental illness or other patients known or suspected to be unable to fully comply with the study protocol;\n* Pregnant or lactating women;\n* HIV-infected individuals.\n* Patients with positive HBsAg test results must undergo HBV DNA testing and can only be enrolled after becoming negative. Additionally, if the HBsAg test result is negative but the HBcAb test result is positive (regardless of the HBsAb status), HBV DNA testing is also required. If the result is positive, treatment must be administered until becoming negative before enrollment;",{"count":309,"type":21},28,[104],"This is an open-label, multicenter clinical study for patients aged 65 and above with double\u002Ftriple-hit diffuse large B-cell lymphoma who are not suitable for transplantation. The study employs a 6-cycle CL-Pola-R-CHP regimen, with cycles repeated every 21 days.",[313,314,27],"DHL","THL",[313,314,82,316],"Chidamide","2026-04-20",{"date":319,"type":34},"2026-04-27",{"date":321,"type":21},"2026-05-01",{"date":323,"type":21},"2028-05-30",{"name":325,"class":41},"Ruijin Hospital",{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":332,"enrollmentInfo":333,"targetDuration":4,"studyType":22,"phases":335,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":349,"leadSponsor":350,"locationsCount":67},"100635131","early-phase-1-a-clinical-study-exploring-the-safety-efficacy-and-metabolic-kinetics-of-ct1182-injection-in-patients-with-relapsed--refractory-non-hodgkin-lymphoma-100635131","NCT07548697","A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed \u002F Refractory Non Hodgkin Lymphoma","Inclusion Criteria:\n\n* voluntarily participate in clinical research; I fully understand and know this study and sign the informed consent form; Willing to follow and be able to complete all research procedures;\n* age 18-75 years (inclusive);\n* r\u002Fr B-NHL diagnosed by histology or cytology includes large B-cell lymphoma, Burkitt lymphoma, mantle cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (hgbl) according to the WHO classification of lymphoproliferation and tumor (5th Edition, 2022); Grade 3B follicular lymphoma (fl3b); Follicular lymphoma (FL) or marginal zone lymphoma (MZL) - transformed DLBCL; Primary mediastinal large B-cell lymphoma (pmbcl); Burkitt lymphoma (BL); Mantle cell lymphoma (MCL).\n* have received standardized systemic treatment in the past, including anti-CD20 drugs (except CD20 negative) and anthracyclines;\n* intolerance during the last treatment, or the investigator assessed the need for new treatment after the last treatment;\n* meet at least one of the following conditions:\n\n  1. According to CT measurement: the long diameter of intranodal lesions is \\>1.5 cm, or the long diameter of extranodal lesions is \\>1.0 cm, and the short diameter can be measured;\n  2. According to PET measurement: FDG uptake score reaches 4 or 5;\n* estimated survival \\>12 weeks;\n* Eastern Cooperative Oncology Group (ECoG) score 0-1;\n* participants should meet the following test results (they have not received any granulocyte colony-stimulating factor (G-CSF) \u002F granulocyte macrophage colony-stimulating factor (GM-CSF) treatment and supportive treatment of red blood cell and platelet transfusion within 7 days before laboratory examination):\n\n  1. ;\n  2. Endogenous creatinine clearance ≥ 50 ml\u002Fmin (using Cockcroft Gault formula), or creatinine ≤ 1.5 × ULN;\n  3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN, total bilirubin ≤ 1.5 × ULN; If lymphoma invades the liver: AST and alt ≤ 5 × ULN, total bilirubin ≤ 3.0 × ULN;\n  4. The international normalized ratio (INR) and activated partial thromboplastin time (APTT) should be ≤ 1.5 × ULN.\n  5. Blood oxygen saturation in non oxygen inhalation state ≥ 92%;\n  6. Left ventricular ejection fraction (LVEF) ≥ 50% (LVEF value is near the critical value, and can be enrolled after the investigator has fully assessed the risk);\n* female participants with childbearing potential must have a pregnancy test at the time of screening and the result is negative. They are willing to use very effective and reliable methods of contraception within 1 year after receiving study treatment. It is absolutely prohibited to donate eggs within 1 year after receiving study treatment infusion during the study period; Male participants who had active sex with women with reproductive potential were willing to use very effective and reliable methods of contraception within 1 year after receiving study treatment. All male participants were absolutely forbidden to donate sperm within 1 year after receiving study treatment infusion during the study period.\n\nExclusion Criteria:\n\n* pregnant or lactating women;\n* research participants with a history of neurological diseases, such as epilepsy, intracranial hemorrhage, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, memory impairment, spinal cord compression, mental disease or any disease involving the central nervous system, or suspected central nervous system (CNS) metastasis;\n* HIV, syphilis infection, active hepatitis B virus infection (HBV-DNA higher than the detection limit or positive), or active hepatitis C virus infection (HCV-RNA positive);\n* according to the investigator's judgment, there is currently any uncontrollable active infection, including but not limited to active tuberculosis;\n* there is known or suspected long-term active infection of EBV and a known history of HLH;\n* have received autologous stem cell transplantation or autologous cell therapy within 3 months before signing the informed consent; Previously received allogeneic stem cell transplantation or allogeneic donor derived cell adoptive therapy;\n* have received previous treatment targeting CD19 (unless the CD19 or CD20 target test is still positive);\n* previously received pseudotyped viral vector related treatment with vesicular stomatitis virus glycoprotein (VSVG) as envelope protein (including but not limited to VSVG pseudotyped lentivirus, adenovirus or other viral vector mediated gene therapy, oncolytic virus therapy, etc.);\n* CT1182 has received anti-tumor treatment within 14 days before infusion or within 5 half lives (whichever is shorter), including but not limited to cytotoxic drugs, targeted therapy, radiotherapy, epigenetic therapy or experimental drug treatment, or has used invasive experimental medical devices. ;\n* receive systemic glucocorticoids equivalent to \\>15 mg\u002F day prednisone within 7 days before signing the informed consent, except for topical glucocorticoids or physiological replacement therapy;\n* have been vaccinated within 4 weeks before signing the informed consent, or it is expected that live attenuated vaccine, inactivated vaccine or RNA vaccine will be vaccinated during the trial or within 12 months after ct1182 infusion;\n* known allergy to ct1182 or any formulation component, allergy or intolerance to tocilizumab, or previous history of other serious allergies such as anaphylactic shock;\n* study participants with any of the following cardiac diseases:\n\n  1. The New York Heart Association (NYHA) cardiac function classification was grade III or IV heart failure;\n  2. Myocardial infarction, unstable angina pectoris, or coronary artery bypass grafting or coronary stent implantation occurred within 6 months before screening;\n  3. There is a history of clinically significant uncontrolled arrhythmias, such as ventricular arrhythmias;\n  4. ;\n  5. Other heart diseases that the investigator believes may endanger the safety of study participants due to participation in this study;\n* suffering from serious lung disease, and participating in this study may endanger the safety of participants according to the judgment of the investigator;\n* the second primary malignant tumor requiring treatment or incomplete remission in the past 3 years, except the following successfully treated tumors with low malignancy such as non metastatic basal cell carcinoma or squamous cell skin carcinoma, non metastatic prostate cancer, breast cancer or cervical cancer in situ, non muscle invasive bladder cancer or thyroid cancer;\n* there is active systemic autoimmune disease, which requires long-term treatment with immunosuppressants;\n* major surgery within 2 weeks before signing the informed consent, or major surgery planned during the study or within 4 weeks after giving the study treatment (excluding cataract and other local anesthesia surgery);\n* the investigator assessed that the participants were unable or unwilling to comply with the requirements of the study protocol, or were not suitable to participate in this clinical study for other reasons.","75 Years",{"count":334,"type":21},24,[336],"EARLY_PHASE1","This study is a single arm, open label, dose exploring clinical study to evaluate the safety, efficacy, metabolic kinetics and pharmacodynamics of CT1182 cells in patients with relapsed \u002F refractory B-cell non Hodgkin lymphoma (r\u002Fr B-NHL).",[339,27,291],"B-cell Non Hodgkin Lymphoma (NHL)",[341,342,343,82,344],"CT1182","CT1182-CG11014","NHL","FL","2026-04-16",{"date":347,"type":34},"2026-04-23",{"date":292,"type":21},{"date":38,"type":21},{"name":351,"class":41},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":22,"phases":361,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":396},"100557911","phase-1-synkir-310-for-relapsedrefractory-b-nhl-100557911","NCT06544265","SynKIR-310 for Relapsed\u002FRefractory B-NHL","A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Adult 18 years of age and older.\n* Histologically confirmed diagnosis of B-NHL before enrollment.\n* Must have received prior CAR T or were unwilling\u002Funable to receive prior CAR T.\n* Must have refractory or relapsed disease after receiving 2 prior lines of therapies.\n* If relapsed\u002Frefractory post-auto-SCT, then must have undergone auto-SCT at least 6 months prior to enrollment.\n* If relapsed\u002Frefractory disease after allogeneic stem cell transplant (allo SCT) then must have undergone allo-SCT at least 6 months prior to enrollment and without evidence of graft versus host disease, and expectation to remain off immunosuppressive therapy through duration of trial\n* Measurable disease at time of enrollment: At least one measurable lesion per Lugano Response Criteria (Cheson et al., 2014) or measurable disease per IWWM-11 response criteria (Treon 2023) for Waldenström macroglobulinemia patients.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n\nExclusion Criteria:\n\n* Previously treated with any investigational agent within 30 days prior to screening.\n* Any previous or concurrent malignancy, with the following exceptions:\n\nAdequately treated non-melanoma skin cancer such as basal cell or squamous cell carcinoma; carcinoma-in-situ (e.g., cervix, bladder, breast) treated curatively and without evidence of recurrence for at least 3 years prior to enrollment or adequately treated melanoma skin cancer in-situ; any other malignancy which has been completely treated and remains in complete remission for ≥ 5 years prior to enrollment. Completely treated prostate cancer with prostate-specific antigen (PSA) level \\\u003C 1.0 may also be permitted.\n\n* Use of systemic immunosuppressive drugs within 4 weeks prior to study entry, or anticipated use of systemic immunosuppressive agents through end of study, with the exception of non-T cell targeting agents prior to leukapheresis\n* Known immunodeficiency disease , with the exception of hypoglobulinemia\n* History or presence of active or clinically relevant primary central nervous system (CNS) disorder, such as seizure, encephalopathy, cerebrovascular ischemia\u002Fhemorrhage, cerebellar disease, or any autoimmune disease with CNS involvement. For primary CNS disorders that have recovered or are in remission, participants without recurrence within 2 years of planned study enrollment may be included.\n* Uncontrolled hypertension, history of myocarditis or congestive heart failure, unstable angina, serious uncontrolled cardiac arrhythmia, or myocardial infarction within 6 months prior to study entry.\n* Any active uncontrolled systemic fungal, bacterial or viral infection.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":360,"type":21},36,[187],"This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed\u002Frefractory B-NHL.",[364,365,366,367,368,369,370,371,372,27,373,374,375,264,376,377,378,379,380,381,382,383,384,82,385,386],"B Cell Lymphoma","NHL, Adult","Mantle Cell Lymphoma","Relapsed Non-Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma","Aggressive B-Cell Non-Hodgkin Lymphoma","Indolent B-Cell Non-Hodgkin Lymphoma","Follicular Lymphoma","Marginal Zone Lymphoma","HGBL With MYC and BCL2 and\u002For BCL6 Rearrangements","High-grade B-cell Lymphoma","Diffuse Large B Cell Lymphoma","T-Cell\u002FHistiocyte Rich Lymphoma","Non-hodgkin Lymphoma,B Cell","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Epstein-Barr Virus Positive DLBCL, Nos","Follicular Lymphoma Grade 3B","DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation","High Grade B-Cell Lymphoma, Not Otherwise Specified","Follicular Lymphoma Grade 3","Marginal Zone Splenic Lymphoma","Waldenstrom Macroglobulinemia","Waldenstrom Macroglobulinaemia","2026-04-08",{"date":389,"type":34},"2026-04-14",{"date":391,"type":34},"2024-11-01",{"date":393,"type":21},"2028-12",{"name":395,"class":66},"Verismo Therapeutics",5,{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":332,"enrollmentInfo":404,"targetDuration":4,"studyType":22,"phases":406,"briefSummary":407,"conditions":408,"keywords":410,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":416,"leadSponsor":418,"locationsCount":67},"100632240","phase-3-a-study-comparing-c-pola-r-chpx-with-cr-chop-in-the-treatment-of-previously-untreated-del-under-the-guidance-of-genotyping-100632240","NCT07511114","A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping","A Prospective, Open-label, Multicenter, Randomized Controlled Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated Double-expression Diffuse Large B-cell Lymphoma Under the Guidance of Genotyping","Inclusion Criteria:\n\n* 1\\. Histopathological diagnosis confirmed as diffuse large B-cell lymphoma, with CD20 positivity;\n* 2\\. Simultaneous expression of MYC and BCL2, according to the WHO standard for immunohistochemistry: MYC ≥ 40%, BCL2 ≥ 50%\n* 3\\. Age ≥ 18 years old and ≤ 75 years old;\n* 4\\. ECOG performance status score of 0, 1, or 2;\n* 5\\. International Prognostic Index (IPI) \\> 1\n* 6\\. No history of malignant tumor; no concurrent occurrence of other tumors;\n* 7\\. Patients with an expected lifespan of at least 6 months, as determined by the researcher;\n* 8\\. The patient or their legal representative must provide written informed consent before undergoing any special examinations or procedures in the study.\n\nExclusion Criteria:\n\n* 1\\. Have previously received systemic or local treatments, including chemotherapy;\n* 2\\. Have previously undergone autologous stem cell transplantation;\n* 3\\. Previously had a history of other malignant tumors, excluding basal cell carcinoma and cervical carcinoma in situ;\n* 4\\. Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, etc;\n* 5\\. Primary central nervous system lymphoma;\n* 6\\. Left ventricular ejection fraction (LVEF) is less than or equal to 50%;\n* 7\\. Laboratory test values during screening: (unless caused by lymphoma); A. Neutrophil count \\\u003C1.5\\*10\\^9\u002FL; B. Platelet count \\\u003C 75 x 10\\^9\u002FL; C. ALT or AST is 2 times higher than the upper limit of normal, and AKP and bilirubin are 1.5 times higher than the upper limit of normal; D. Creatinine level is higher than 1.5 times the upper limit of normal;\n* 8\\. Other concurrent and uncontrolled medical conditions that the researcher believes will affect the patient's participation in the study.\n* 9\\. Patients with mental illness or other patients known or suspected to be unable to fully comply with the study protocol;\n* 10\\. Pregnant or lactating women;\n* 11\\. Individuals infected with HIV.\n* 12\\. Patients with positive HBsAg test results must undergo HBV DNA testing and can only be enrolled after becoming negative. Additionally, if the HBsAg test result is negative but the HBcAb test result is positive (regardless of the HBsAb status), HBV DNA testing is also required. If the result is positive, treatment must be administered until becoming negative before enrollment;",{"count":405,"type":21},156,[54],"Evaluate the efficacy and safety of C Pola R-CHP+X compared to CR-CHOP in the treatment of previously untreated patients with DEL",[27,409],"Double Expressor Lymphoma",[82,411,316],"DEL","2026-03-31",{"date":414,"type":34},"2026-04-06",{"date":412,"type":21},{"date":417,"type":21},"2030-03-31",{"name":325,"class":41},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":426,"targetDuration":428,"studyType":429,"phases":4,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":438,"locationsCount":67},"100553110","glofitamab-in-chinese-patients-with-rr-dlbcl-100553110","NCT06481826","Glofitamab in Chinese Patients With R\u002FR DLBCL","A Study to Evaluate Glofitamab as Single Agent in Chinese Patients With Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n1. Histologically-confirmed DLBCL\n2. Participants must have relapsed or failed to respond to at least two lines of prior systemic therapy\n3. Participants must have measurable disease\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding\n2. Patient with known active infection, or reactivation of a latent infection\n3. Patient with active autoimmune disease or immune deficiency\n4. severe organ failure：LVEF\\\u003C40%；DLCO\\\u003C40%；eGFR\\\u003C30ml\u002Fmin；Bilirubin≥3ULN\n5. Patients who are dependent on the sponsor, the investigator or the trial site",{"count":427,"type":21},20,"3 Years","OBSERVATIONAL","This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R\u002FR) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.",[27],"2026-03-23",{"date":434,"type":34},"2026-03-27",{"date":436,"type":34},"2024-01-01",{"date":38,"type":21},{"name":439,"class":41},"Peking Union Medical College Hospital",{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":447,"targetDuration":448,"studyType":429,"phases":4,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":67},"100629280","real-world-effectiveness-and-safety-of-glofitamab-in-primary-refractory-and-early-relapsed-diffuse-large-b-cell-lymphoma-100629280","NCT07472621","Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma","Efficacy and Safety of Glofitamab in the Real-World Treatment of Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\n  1. Age ≥18 years at the time of treatment initiation.\n  2. Histologically or pathologically confirmed diffuse large B-cell lymphoma (DLBCL).\n  3. Patients with primary refractory disease or early relapse, defined as:\n\n     Failure to achieve complete response (CR) after at least 4 cycles of first-line induction therapy, or\n\n     Relapse confirmed by imaging within 12 months after achieving CR following first-line therapy.\n  4. Patients who plan to initiate a glofitamab-containing treatment regimen (either monotherapy or combination therapy) within 12 months after study initiation.\n  5. Willing and able to comply with study follow-up and data collection requirements.\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\n  1. Currently participating in, or planning to participate in, any interventional clinical trial.\n  2. Any condition that, in the investigator's judgment, would make the patient unsuitable for participation in this study (e.g., inability to complete follow-up, safety concerns, or significant comorbidities).",{"count":427,"type":21},"20 Years","This is a prospective, observational, non-interventional real-world study that will not alter participants' routine clinical care. Approximately 20 eligible patients with diffuse large B-cell lymphoma (DLBCL) will be enrolled. Treatment decisions will be made by the treating physician based on standard clinical practice and may include glofitamab monotherapy or glofitamab-based combination regimens, such as glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) or glofitamab plus polatuzumab-based therapy (Glofit-Pola).\n\nThe study will collect baseline characteristics (including age, sex, medical history, and molecular subtype), treatment information, laboratory test results, adverse events, and survival follow-up data. Circulating tumor DNA (ctDNA) testing will be performed to assess minimal residual disease (MRD) in peripheral blood. When clinically indicated, cerebrospinal fluid samples may be collected to measure drug concentration.\n\nAll personal information will be kept strictly confidential. Identifiable information will be removed and replaced with coded study numbers. Medical records will be maintained at the study site and accessed only by authorized research personnel. Representatives from the sponsor, ethics committee, or regulatory authorities may review study records as required. Study results will be published in aggregated form without including any information that could identify individual participants. Study data and personal information will be used solely for research purposes.",[27],"2026-03-11",{"date":453,"type":34},"2026-03-16",{"date":455,"type":21},"2026-03-10",{"date":457,"type":21},"2028-12-01",{"name":459,"class":460},"Henan Cancer Hospital","OTHER_GOV",{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":22,"phases":470,"briefSummary":471,"conditions":472,"keywords":473,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":4},"100622879","modified-r-mine-regimen-vs-r-gemox-regimens-on-the-treatment-of-late-relapsed-dlbcl-100622879","NCT07389356","Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL","Rituximab, Ifosfamide, Mitoxantrone Liposome, Etoposide (Modified R-MINE) Regimen vs. Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) Regimen in the Treatment of Late Relapsed Diffuse Large B-cell Lymphoma: A Multicenter, Open, Randomized, Controlled, Phase II Study","Inclusion Criteria:\n\n* They voluntarily participated in the study and signed the informed consent.\n* Age 18 or higher;\n* Expected survival time for 3 months or more;\n* The histopathological diagnosed late relapsed (\\> 12 months) diffuse large B cell lymphoma;\n* Must have at least a Lugano 2014 standard can be evaluation or measurable lesions: lymph node lesions, measurable lymph nodes should be diameter \\> 1.5 cm; Non-lymph node lesions, measurable extranodal lesions should be diameter \\> 1.0 cm;\n* ECOG score 0 to 2 points;\n* Bone marrow function: neutrophil count \\>= 1.5 x 10\\^9 \u002F L, platelet count \\>= 75 x 10\\^9 \u002F L, and hemoglobin \\>= 80 g\u002FL (neutrophil count may be extended to \\>= 1.0 x 10\\^9 \u002F L, the platelet count can be extended to \\>= 50 x 10\\^9 \u002F L, and hemoglobin can be extended to \\>= 75 g\u002FL in patients with bone marrow involvement);\n* Liver and kidney function: serum creatinine acuities were \\\u003C= 1.5 times the upper limit of normal (ULN) value; AST and ALT \\\u003C= 2.5 times the ULN(\\\u003C= 5 times the upper limit of normal in patients with liver invasion); Total bilirubin \\\u003C= 1.5 times the ULN (\\\u003C= 3 times the upper limit of normal in patients with liver invasion);\n* Blood coagulation function: International standardization Ratio (International Normalized thewire, INR) \\\u003C= 1.5 x ULN; Prothrombin Time (PT), Activated PartialThromboplastin Time (APTT) \\\u003C= 1.5×ULN (unless receiving anticoagulant therapy, And PT and APTT at screening were within the expected range for anticoagulant therapy).\n\nExclusion Criteria:\n\n* Previous history of antitumor therapy meeting any of the following conditions:\n\n  1. Prior treatment with mitoxantrone or liposomal mitoxantrone;\n  2. Prior treatment with doxorubicin or other anthracyclines, with a total cumulative doxorubicin dose \\>360 mg\u002Fm² (for other anthracyclines, 1 mg of doxorubicin is equivalent to 2 mg of epirubicin);\n  3. Prior autologous hematopoietic stem cell transplantation within 100 days before the first dose, or a history of allogeneic hematopoietic stem cell transplantation;\n  4. Prior antitumor therapy (including chemotherapy, targeted therapy, hormone therapy, traditional Chinese medicine with antitumor activity, etc.) or participation in other clinical trials involving investigational drugs within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of the study drug.\n* Hypersensitivity to any study drug or its components;\n* Uncontrolled systemic diseases (e.g., progressive infections, uncontrolled hypertension, diabetes, etc.);\n* Cardiac function and diseases meeting any of the following conditions:\n\n  1. Long QTc syndrome or QTc interval \\>480 ms;\n  2. Complete left bundle branch block, complete right bundle branch block with left anterior fascicular block, type II second-degree or third-degree atrioventricular block;\n  3. Severe, uncontrolled arrhythmia requiring medication;\n  4. New York Heart Association Class ≥ III;\n  5. History of acute myocardial infarction, unstable angina, severe unstable ventricular arrhythmia, or any other arrhythmia requiring treatment within 6 months before enrollment; history of clinically significant pericardial disease; or electrocardiographic evidence of acute ischemic or active conduction system abnormalities.\n* Active hepatitis B or C infection (hepatitis B surface antigen positive with HBV DNA \\>1×10³ copies\u002FmL; HCV RNA \\>1×10³ copies\u002FmL);\n* Human immunodeficiency virus (HIV) infection (HIV antibody positive);\n* History or concurrent presence of other malignancies (except for effectively controlled non-melanoma skin basal cell carcinoma, in situ carcinoma of the breast\u002Fcervix, and other malignancies effectively controlled without treatment in the past five years);\n* Presence of primary or secondary central nervous system (CNS) lymphoma or a history of CNS lymphoma at enrollment;\n* Pregnant or lactating women, and patients of childbearing potential unwilling to use contraception;\n* Requirement for systemic corticosteroid therapy or other immunosuppressive therapy due to a medical condition within 14 days before the start of study treatment \\[topical use (ocular, intra-articular, intranasal, and inhaled corticosteroids with minimal systemic absorption) is permitted; short-term (≤7 days) corticosteroid use for prophylaxis (e.g., contrast agent allergy) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity due to contact allergens) is permitted\\];\n* Other conditions deemed by the investigator to be unsuitable for participation in this study.",{"count":469,"type":21},70,[24],"This study was a multicenter, open, randomized controlled, phase II clinical study. Is expected in 70 cases of late relapsed diffuse large B cell lymphoma, were randomly assigned to receive mitoxantrone liposomes modified R - MINE plan or R - GemOx treatment. Each cycle was 3 weeks (21 days) for a total of 4 cycles. Subjects assigned to each signed informed consent to screening, screening, in the center of the study determined in accordance with the order signed informed consent. Before the start of the trial, the number of random seeds was set by the statistician, and the block randomization method was used to generate the subject random table using R 4.3.3 (or above). The random ratio between the modified R-mine group and the R-Gemox group was 1:1. After the investigator determined that the subjects were screened successfully, the subjects were randomly numbered according to the order in which the eligible subjects were screened successfully. The intervention was performed by the principal investigator or by someone designated by the principal investigator. Study includes screening period (the first 28 days), treatment period (plan 4 cycles, treatment after 2 cycles enhanced CT\u002FMRI or PET - CT mid-term efficacy, PET - CT curative effect evaluation) after treatment, follow-up (follow-up curative effect, safety and survival follow-up follow-up). Participants provided written informed consent and underwent baseline examinations during the screening period. Participants who met the inclusion criteria and none of the exclusion criteria entered the treatment period. All the study participants completed protocol-specified examinations during the course of treatment to observe efficacy and safety. The end of the treatment period was followed by the follow-up period.",[27],[82,474],"Mitoxantrone Hydrochloride liposomal","2026-01-28",{"date":477,"type":34},"2026-02-05",{"date":479,"type":21},"2026-02-25",{"date":481,"type":21},"2029-12-30",{"name":483,"class":41},"The First Affiliated Hospital with Nanjing Medical University",{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":22,"phases":493,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":67},"100581142","phase-2-zanubrutinib-in-patients-with-dlbcl-and-myd88-or-notch1-mutation-or-cd5-100581142","NCT06846463","Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+","Phase 2 Trial Utilizing Zanubrutinib in Patients With Diffuse Large B-cell Lymphoma and MYD88 L265P Mutations, CD79B Mutations, NOTCH1 Truncation or Who Are CD5+ by IHC.","Inclusion Criteria:\n\n* Patients must have a documented pathologic diagnosis of DLBCL at any stage.\n* Must have documented MYD88 L265P, CD79B, or NOTCH1 truncation mutation or be CD5+ by IHC.\n* Age ≥18 years on the day of signing the informed consent form.\n* Patients must have measurable disease on Positron Emission Tomography-Computed Tomography scan (CT\u002FPET) imaging.\n* Patient must have received no more than one cycle of R-CHOP prior to enrollment. Length of time between first R-CHOP treatment and planned 2nd R-CHOP treatment should vary by no more than 21 days ± 3 days.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.\n* Adequate bone marrow function as defined by:\n\n  * Absolute neutrophil count (ANC) ≥1000\u002Fmm3, except for patients with bone marrow involvement in which ANC must be ≥500\u002Fmm3.\n  * Platelet ≥75,000\u002Fmm3, except for patients with bone marrow involvement in which the platelet count must be ≥30,000\u002Fmm3.\n  * Hemoglobin ≥7 g\u002FdL, after transfusion if necessary\n* Adequate organ function defined as:\n\n  * Creatinine clearance ≥30 mL\u002Fmin as estimated by the Cockcroft-Gault equation.\n  * Aspartate aminotransferase (AST)\u002Fserum glutamic oxaloacetic transaminase, and alanine aminotransferase (ALT)\u002Fserum glutamic pyruvic transaminase ≤2.5 × upper limit of normal (ULN).\n  * Serum total bilirubin ≤3 x ULN (except patients with Gilberts syndrome 3g\u002Fdl).\n* Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.\n* Women of childbearing potential and men must agree to use one of the following highly effective forms of birth control during the treatment and for 1 month following completion of study treatment for women and for 1 week following completion of study treatment for men.\n\n  * combined (estrogen and progestogen containing) hormonal contraception:\n* oral\n* intravaginal\n* transdermal\n\n  * progestogen-only hormonal contraception associated with inhibition of ovulation\n* oral\n* injectable\n* implantable\n\n  * intrauterine device (IUD)\n  * intrauterine hormone-releasing system (IUS)\n  * bilateral tubal occlusion\n  * vasectomized partner\n  * heterosexual abstinence\n* Patients must not have any known allergies, hypersensitivity or intolerance to corticosteroids or monoclonal antibodies.\n* Able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments.\n\nExclusion Criteria:\n\n* Patients with high grade B-cell lymphoma with myelocytomatosis oncogene \u002Fimmunoglobulin heavy-chain (MYC)\u002FIGH and BCL-2 rearrangements.\n* Patients with brain metastasis.\n* Patients with peripheral neuropathy CTCAE grade ≥2.\n* Any uncontrolled or clinically significant cardiovascular disease including the following:\n\n  * Myocardial infarction within 6 months before screening.\n  * Unstable angina within 3 months before screening.\n  * New York Heart Association class III or IV congestive heart failure.\n  * History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes).\n* Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 prostate cancer.\n* History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention.\n* History of stroke or intracranial hemorrhage within 6 months before first dose of study drug.\n* Severe or debilitating pulmonary disease in the opinion of the treating investigator.\n* Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.\n* Active fungal, bacterial and\u002For viral infection requiring systemic therapy.\n* Underlying medical conditions that, in the investigator's opinion, will render the administration of study drug hazardous or obscure the interpretation of toxicity or AEs.\n* Active infection with HIV, or serologic status reflecting active hepatitis B or C infection as follows:\n\n  * Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Patients with presence of HBcAb, but absence of HBsAg, are eligible if hepatitis B virus (HBV) DNA is undetectable (\\\u003C 20 IU), and if they are willing to undergo monitoring every 4 weeks for HBV reactivation.\n  * Presence of hepatitis C virus (HCV) antibody. Patients with presence of HCV antibody are eligible if HCV RNA is undetectable.\n* Major surgery within 4 weeks of the first dose of study drug.\n* Pregnant or lactating women.\n* Left ventricular ejection fraction (LVEF) \\\u003C55% on screening echocardiogram.\n* Vaccination or requirement for vaccination with a live vaccine within 28 days prior to the first dose of study drug or at any time during planned study treatment.\n* Hypersensitivity to zanubrutinib, rituximab, cyclophosphamide, doxorubicin, vincristine, or prednisone.\n* Requires ongoing treatment with a strong CYP3A inducer (Table 3).\n* Concurrent participation in another therapeutic clinical trial.\n* Active and\u002For ongoing autoimmune anemia and\u002For autoimmune thrombocytopenia (eg, idiopathic thrombocytopenia purpura).\n* Requires ongoing treatment with warfarin or warfarin derivatives.",{"count":492,"type":21},21,[104],"This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).",[496,27],"Diffuse Large B-cell Lymphoma","2026-01-21",{"date":499,"type":34},"2026-01-23",{"date":501,"type":34},"2025-05-27",{"date":503,"type":21},"2032-07-31",{"name":505,"class":41},"Virginia Commonwealth University",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":22,"phases":516,"briefSummary":517,"conditions":518,"keywords":520,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":528,"locationsCount":396},"100615151","phase-2-daly-ii-japanmb-cart20191-for-dlbcl-100615151","NCT07288879","DALY II Japan\u002FMB-CART2019.1 for DLBCL","A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and\u002For Refractory Diffuse Large B Cell Lymphoma.","DALY II Japan","Inclusion Criteria:\n\n1. Histologically confirmed DLBCL or associated subtype, defined by WHO 2016 classification:\n\n   * DLBCL not otherwise specified (NOS)\n   * High-grade B-cell lymphoma with MYC and BCL2 and\u002For BCL6 rearrangements\n   * High-grade B-cell lymphoma, NOS\n   * Primary mediastinal (thymic) large B-cell lymphoma\n   * Transformed lymphoma (e.g. transformed follicular or marginal zone lymphoma, follicular lymphoma Grade 3B)\n2. Relapsed or refractory disease after 2 or more lines of chemotherapy including rituximab and anthracycline and either having failed autologous stem cell transplant (ASCT), or being ineligible for or not consenting to ASCT 2.1 Chemotherapy-refractory disease is defined as one of the following:\n\n   * No response to last line of therapy:\n\n     * Progressive disease (PD) as best response to most recent therapy regimen\n     * Stable disease (SD) as best response to most recent therapy with duration no longer than 6 months from last dose of therapy OR\n   * Relapsed or persistent disease after prior ASCT for lymphoma\n\n     * Disease progression or relapse less than or equal to 24 months of ASCT\n     * If salvage therapy is given post-ASCT, the individual must have had no response to or relapsed after the last line of therapy 2.2 Disease relapse in subjects without prior ASCT is defined as relapse of disease in ≤ 12 months after the last dose of most recent therapy regimen 2.3 Ineligible for ASCT is defined as meeting one of the following criteria:\n   * Chemotherapy-refractory disease after salvage therapy\n   * Disease progression or relapse ≤ 12 months after salvage therapy\n   * Intolerance to salvage therapy\n\n   In addition, all subjects must have:\n3. Age ≥18 years\n4. Eastern Cooperative Oncology Group (ECOG) performance status that is either 0 or 1 at screening. ECOG performance status of 2 at screen is allowed if the decrease in performance status is due to DLBCL\n5. Measurable disease according to Lugano 2014 criteria for assessing fluorodeoxyglucose-positron emission tomography (FDG-PET)\u002Fcomputer tomography (CT) in lymphoma (Cheson et al, 2014)\n6. CD19 or CD20 antigen expression on tumor is not required after the most recent chemoimmunotherapy; however, 6.1 Subject must have at least 20 unstained slides of tissue available prior to MB-CART2019.1 infusion 6.2 If archival tissue is not available, subject must be willing to undergo attempted repeat biopsy\n7. No clinical suspicion of central nervous system (CNS) lymphoma\n8. If the subject has history of CNS disease, then he\u002Fshe must 8.1. Have no signs or symptoms of CNS disease 8.2. Have no active disease on magnetic resonance imaging (MRI) 8.3. Have no large cell lymphoma present in cerebral spinal fluid (CSF) on cytospin preparation and flow cytometry, regardless of the number of white blood cells (WBCs)\n9. If the subject has history of cerebral vascular accident (CVA) 9.1. The CVA event must be greater than 12 months prior to leukapheresis 9.2. Any neurological deficits must be stable\n10. An estimated creatinine clearance by Cockcroft-Gault Equation (eGFR) \\> 60mL\u002Fmin\n11. Cardiac ejection fraction (EF) ≥ 45% as determined by an echocardiogram (ECHO)\n12. Resting O2 saturation \\>90% on room air\n13. Serum alanine aminotransferase (ALT) \u002F aspartate aminotransferase (AST) \\\u003C5 times the Upper Limit of Normal (ULN) for age\n14. Total bilirubin \\\u003C1.5 mg\u002Fdl, except in individuals with Gilbert's syndrome\n15. Absolute neutrophil count (ANC) \\> 1000\u002FμL\n16. Absolute lymphocyte count \\> 100\u002FμL\n17. Platelet count \\> 50,000\u002FμL\n18. Estimated life expectancy of more than 3 months other than primary disease\n19. Subjects of childbearing or child fathering potential must be willing to practice birth control from the time of enrollment on this study until the follow-up period of the study\n\nExclusion Criteria:\n\n1. Primary CNS lymphoma\n2. Richter's transformed DLBCL arising from chronic lymphocytic leukemia (CLL)\n3. Unable to give informed consent\n4. Known history of infection with human immunodeficiency virus (HIV) or active hepatitis B (HBsAg positive), unless confirmed to be polymerase chain reaction (PCR) negative; antiviral prophylaxis is required as recommended in the Japanese guidelines for Hepatitis B treatment if HBsAg negative and anti-HBc positive\n5. Known history of infection with hepatitis C virus (anti-HCV positive) unless viral load is undetectable per quantitative PCR and\u002For nucleic acid testing\n6. Known history of active seizure or presence of seizure activities or on active anti-seizure medications within the prior 12 months\n7. Known history of CVA within prior 12 months\n8. Known history or presence of autoimmune CNS disease, such as multiple sclerosis, optic neuritis or other immunologic or inflammatory disease\n9. Presence of active CNS disorder that, in the judgment of the investigator, may impair the ability to evaluate neurotoxicity\n10. Active systemic fungal, viral or bacterial infection\n11. Pregnant or breast-feeding woman\n12. Previous or concurrent malignancy with the following exceptions:\n\n    * Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to study entry)\n    * In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 2 years prior to the study\n    * Adequately treated breast or prostate carcinoma on hormonal therapies such as Lupron or tamoxifen and in clinical remission of ≥ 2 years\n    * A primary malignancy which has been completely resected \u002F treated with curative intent and in complete remission of ≥ 2 years\n13. History of non-neurologic autoimmune disease (e.g. Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) requiring systemic immunosuppressive or systemic disease modifying agents within the last 2 years\n14. Medical condition requiring prolonged use of systemic corticosteroids equivalent to Prednisone \\>10 mg\u002Fday\n15. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 6 months of enrollment\n16. Concurrent radiotherapy (allow up to time of leukapheresis)\n17. Baseline dementia that would interfere with therapy or monitoring, determined using Immune Effector Cell-Associated Encephalopathy (ICE) Assessment at baseline. (Appendix 6, Section 13.6)\n18. History of severe immediate hypersensitivity reaction to any of the agents used in this study\n19. Refusal to participate in additional lentiviral gene therapy LTFU protocol\n20. Prior CAR T cell therapy for any indication\n21. Prior allogeneic stem cell transplant for any indication.\n22. Prior bispecific antibodies for cancer therapy\n23. Prior T cell receptor-engineered T cell therapy\n24. Prior anti CD 19 immunotherapy\n25. Hypersensitivity against any drug including MB-CART2019.1 (and the constituents used in the production, ingredients\u002Fimpurities, including bovine and rodent-derived components), that is scheduled or likely to be given during trial participation, e.g. as part of the mandatory preparative chemotherapy or rescue medication\u002Fsalvage therapies for treatment related toxicities.",{"count":515,"type":21},31,[104],"DALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and\u002For refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy.",[27,519],"CAR T Cell Therapy",[521,82],"CAR T Cell therapy","2026-01-06",{"date":524,"type":34},"2026-01-08",{"date":526,"type":34},"2025-12-11",{"date":38,"type":21},{"name":529,"class":66},"Miltenyi Biomedicine GmbH",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":22,"phases":540,"briefSummary":541,"conditions":542,"keywords":543,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":7},"100532993","phase-3-prevention-of-anthracycline-induced-cardiac-dysfunction-with-dexrazoxane-in-patients-with-diffuse-large-b-cell-lymphoma-100532993","NCT06220032","Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label Trial","HO170DLBCL","Inclusion Criteria:\n\n1. Untreated patients with a confirmed histologic diagnosis of CD20+ DLBCL according to WHO classification 2022:\n\n   * DLBCL, not otherwise specified (NOS)\n   * High-grade B-cell lymphoma NOS\n   * High-grade B-cell lymphoma with MYC and BCL2 and\u002For BCL6 translocation when DA-EPOCH-R is not an option. R2- CHOP is allowed.\n   * Follicular lymphoma\n   * T-cell\u002Fhistiocyte-rich B cell lymphoma (THRBCL)\n\n   Note: Transformed, previously untreated lymphoma is allowed.\n\n   Note: 5-day treatment of dexamethasone 15 mg\u002Fday or prednisone 100 mg\u002Fday or local radiotherapy in order to control life-threatening\u002Finvalidating tumor related symptoms is allowed.\n\n   Note: It is allowed to start with a first cycle of R-CHOP21 pending the FISH results.\n2. Planned treatment with 6 R-CHOP21. The following regimens are also allowed:\n\n   * Treatment with reversed R-CHOP21\n   * Treatment with R2-CHOP21 (6 R-CHOP21 + lenalidomide 15 mg day 1-14) in case of double hit lymphoma\n   * Two additional administrations of rituximab after 6 cycles of R-CHOP21\n   * High dosis MTX and\u002For MTX-it for CNS prophylaxis\n3. Ann Abor stages II-IV and stage I if the treatment plan is 6 R-CHOP21 in case of bulky disease (defined as a ≥10 cm mass);\n4. Age ≥ 18 years;\n5. WHO performance status ≤ 2, WHO 3 performance status is allowed when considered directly related to the DLBCL;\n6. Negative pregnancy test at study entry for women of childbearing potential;\n7. Female patient is either post-menopausal for at least 1 year before the screening visit or surgically sterile or if of childbearing potential, agrees to practice two effective methods of contraception, at the same time, from the time of signing the informed consent through at least 12 months after the last dose of protocol treatment, or agrees to completely abstain from heterosexual intercourse;\n8. Male patient, even if surgically sterilized, (i.e., status post vasectomy) agrees to practice effective barrier contraception during the entire study period and through 12 months after the last dose of protocol treatment, or agrees to completely abstain from heterosexual intercourse;\n9. Patient is able to adhere to the study visit schedule and other protocol requirements;\n10. Written informed consent.\n\nExclusion Criteria:\n\n1. Any of the following B-cell lymphomas according to WHO classification 2022:\n\n   o Central Nervous System involvement by DLBCL;\n\n   Note: high CNS-IPI is allowed\n   * Testicular DLBCL;\n   * Primary mediastinal B-cell lymphoma;\n   * Epstein-Barr virus (EBV) post-transplant lymphoproliferative disorder;\n2. Any prior malignancy or present malignancy other than DLBCL that required or requires systemic therapy. Prior surgery or local radiotherapy is allowed in case the heart has not been exposed.\n3. Patients requiring treatment with mini-R-CHOP\n4. Pre-existing cardiac disease including:\n\n   * LVEF \\\u003C50% measured with echocardiography (2D or 3D)\n   * Symptomatic heart failure (NYHA ≥II) or hospitalization for heart failure in the last year;\n   * Refractory anginal symptoms\n   * Cardiac arrhythmias not controlled with optimal medical treatment, in case of atrial fibrillation the ventricular response needs to be \\\u003C110\u002Fmin;\n   * Significant valvular dysfunction on echocardiography;\n   * Non-ischemic cardiomyopathy\n5. Non-diagnostic\u002Fpoor transthoracic echocardiography imaging quality at baseline;\n6. Severe pulmonary dysfunction defined as breathlessness at rest (COPD GOLD III or IV), unless clearly related to DLBCL;\n7. Severe neurological or psychiatric disease;\n8. Inadequate hematological function (absolute Neutrophil Count (ANC) \\\u003C1.0x109\u002FL or platelets \\\u003C75x109\u002FL), unless clearly related to DLBCL;\n9. Significant hepatic dysfunction (serum bilirubin or transaminases ≥ 3 times the upper limit of normal) unless related to lymphoma infiltration of the liver;\n10. Active hepatitis B or C infection (serology testing is required at screening). Patients positive for hepatitis B surface antigen (HBsAg) regardless of antibody status or HBsAg negative but anti-HBc positive are only eligible if HBV-PCR is negative and patients are protected with lamuvidine or entecavir. Patients with positive hepatitis C serology are only eligible if HCV-(RNA) is confirmed negative;\n11. Significant renal dysfunction (creatinine clearance \\\u003C 30 ml\u002Fmin after rehydration) or requiring dialysis;\n12. Active uncontrolled fungal, bacterial and\u002For viral infection;\n13. Patient known to be HIV-positive;\n14. Breast-feeding female patients;\n15. Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule;\n16. Participation in another clinical trial with anti-cancer therapy or a cardiovascular drug.",{"count":539,"type":21},324,[54],"Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity. Thereby patients treated for this malignancy are at double the risk of developing symptomatic heart failure \u002F cardiomyopathy when compared to the general population. This corresponds to a cumulative incidence of 5-10% within 5-years after receiving R-CHOP. In the elderly, an incidence of 26% has been reported after 8-years of follow-up. Among patients who die in complete remission, heart failure has been described to be one of the most important causes of death. ANTICIPATE aims to evaluate if dexrazoxane can prevent AICD in DLBCL patients and identify those at highest risk of AICD. Of all patients treated with anthracyclines in a first-line setting, DLBCL patients were chosen for this trial for two primary reasons. Firstly, these patients have a favourable oncological prognosis with a 5-year relative survival in the Netherlands of 64-78% in those aged 18-74 years increasing the importance of preventing long-term toxicity. Secondly, the cumulative anthracycline dose used for the treatment of DLBCL is higher than the dose used in breast cancer. The cumulative anthracycline dose is the most important risk factor for AICD known.",[27],[544,545,546,547,548,549,344,550,551],"dexrazoxane","primary prevention","cardiotoxicity","heart failure","diffuse large B-cell lymphoma","R-CHOP","R2CHOP","LVEF","2026-01-02",{"date":554,"type":34},"2026-01-05",{"date":556,"type":34},"2024-08-15",{"date":558,"type":21},"2028-12-15",{"name":560,"class":41},"Stichting Hemato-Oncologie voor Volwassenen Nederland",{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":22,"phases":569,"briefSummary":570,"conditions":571,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":4},"100618034","phase-2-glofitamab-combined-with-car-t-therapy-in-rr-dlbcl-100618034","NCT07326371","Glofitamab Combined With CAR-T Therapy in R\u002FR DLBCL","A Single-Center, Prospective Study Evaluating the Efficacy and Safety of Glofitamab Combined With CAR-T Therapy in Patients With High-Risk Relapsed\u002FRefractory Large B-Cell Lymphoma","Inclusion Criteria:\n\n* Signed Informed Consent Form\n* Histologically confirmed large B==cell lymphoma with CD19 and CD20 expression, including diffuse large B==cell lymphoma (DLBCL) not otherwise specified (NOS); primary mediastinal large B==cell lymphoma (PMBCL); high==grade B==cell lymphoma (HGBL); and DLBCL transformed from follicular lymphoma\n* Patients who have relapsed after at least one prior line of therapy or are refractory, including those who have received anthracycline==containing chemotherapy regimens and anti==CD20 monoclonal antibody therapy\n* Patients must be willing to receive CAR==T and Glofitamab therapy and be deemed suitable for CAR==T and Glofitamab treatment by the investigator\n* Presence of at least one high==risk prognostic factor: (1) extranodal involvement; (2) maximum tumor diameter \\> 4 cm; (3) TP53 mutation\n* No CNS involvement\n* ECOG Performance Status of 0, 1, or 2\n* Life expectancy ≥12 weeks\n* Adequate hematologic function (unless due to underlying disease, such as extensive bone marrow involvement, or secondary to lymphoma==related splenomegaly as determined by the investigator, but transfusion of blood products is allowed) and adequate liver, renal, pulmonary, and cardiac function, defined as follows:\n\n  * Neutrophil count ≥ 1.0 × 10\\^9\u002FL, platelet count ≥ 50 × 10\\^9\u002FL, lymphocyte count ≥ 0.1 × 10\\^9\u002FL\n  * ALT\u002FAST ≤ 2.5 × ULN and total bilirubin \\\u003C 1.5 × ULN (except for participants with Gilbert's syndrome or lymphoma involvement of the liver)\n  * Creatinine clearance ≥ 30 mL\u002Fmin\n  * Pulmonary function: ≤ CTCAE grade 1 dyspnea, oxygen saturation (SpO2) ≥ 92% on room air\n  * Cardiac function: LVEF ≥ 40%\n* Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to initiating study treatment. Women who are postmenopausal (defined as no menses for ≥ 12 months without an alternative medical cause) or have undergone surgical sterilization (removal of ovaries and\u002For uterus) are not required to undergo a pregnancy test\n* For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agree to refrain from donating eggs\n* For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agree to refrain from donating sperm\n* Patients with a distant history of autoimmune disease or well==controlled autoimmune disease may be eligible for enrollment at the investigator's discretion\n\n  * Patients with a history of autoimmune==related hypothyroidism who are on a stable dose of thyroid replacement hormone may be eligible for this study\n  * Patients with a history of disease==related immune thrombocytopenic purpura or autoimmune hemolytic anemia may be eligible for this study\n  * Patients with a history of type 1 diabetes mellitus who are well controlled (defined as hemoglobin A1c \\\u003C 8% at screening and no episodes of diabetic ketoacidosis) are eligible for this study\n  * Patients with eczema, psoriasis, chronic lichen simplex, or vitiligo with only skin involvement (e.g., excluding psoriatic arthritis) are eligible for this study if they meet all of the following conditions： Rash must cover \\\u003C 10% of body surface area The disease is well controlled at baseline and only requires low==potency topical corticosteroids No acute exacerbations of an underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologics, oral calcineurin inhibitors, or high==potency oral corticosteroids within the past 12 months\n* Subjects with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 2 years and have no residual neurological deficits, as determined by the investigator, may participate in this study\n\nExclusion Criteria:\n\n* History of allergic reactions to compounds with similar chemical or biological composition to axi==cel, relma==cel, glofitamab, obinutuzumab, or other drugs used in the study.\n* Active or uncontrolled infections requiring systemic therapy (including fungal, bacterial, viral, etc.)\n* History of allogeneic hematopoietic stem cell transplantation\n* History of organ transplantation\n* Viral infections deemed uncontrollable by antiviral medications, as determined by the investigator, including:\n\n  * Active hepatitis B virus (HBV) infection with HBV DNA ≥ 500 IU\u002FmL (2500 copies\u002FmL)\n  * Positive hepatitis C virus (HCV) RNA test\n  * Positive human immunodeficiency virus antibody (HIV==Ab) test\n  * Positive Treponema pallidum antibody (TP==Ab) test\n  * Cytomegalovirus (CMV) DNA levels above the upper limit of normal\n  * Epstein==Barr virus (EBV) DNA levels above the upper limit of normal\n* Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease\n* Presence of brain metastases or active primary central nervous system lymphoma\n* Significant or extensive history of cardiovascular disease such as New York Heart Association Class III or IV cardiac disease or Objective Assessment Class C or D, myocardial infarction within the last 6 months prior to the start of Cycle 1, unstable arrhythmias, or unstable angina\n* Presence of severe genetic disorders or severe autoimmune diseases, including but not limited to myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome==associated vascular thrombosis, Wegener's granulomatosis, Sjögren's syndrome, Guillain==Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis\n* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)\n* Thromboembolic events (e.g., myocardial infarction, pulmonary embolism, deep vein thrombosis, or other systemic embolic events) within 6 months prior to screening\n* Malignancies other than the indication for this trial within 5 years prior to screening, except for in situ cancers (e.g., cervical, bladder, breast) or non==melanoma skin cancers\n* Receipt of chemotherapy drugs, tumor radiotherapy, or immunosuppressive antibodies such as anti==TNF, anti==IL6, or anti==IL6R within 4 weeks or 5 half==lives (whichever is shorter) prior to mononuclear cell collection\n* Vaccination with live, attenuated vaccines within 3 months prior to mononuclear cell collection, or expected need for such vaccination during the trial\n* Currently pregnant or breastfeeding, or planning to become pregnant during the study or within 12 months after the last dose\n* Patients currently participating in other clinical trials (e.g., new drug clinical trials, registration studies, investigator==initiated clinical studies)\n* Deemed unsuitable for this clinical trial by the investigator (e.g., poor compliance, substance abuse)\n* Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the study protocol or interpretation of results\n* Any other diseases, metabolic dysfunctions, physical examination findings, or clinical laboratory results that reasonably suggest the presence of a condition that contraindicates the use of the investigational drug",{"count":334,"type":21},[104],"This study is a single-center, open-label, prospective study aimed at evaluating the efficacy and safety of Glofitamab combined with CAR-T therapy in patients with high-risk relapsed\u002Frefractory large B-cell lymphoma.",[27],"2025-12-26",{"date":524,"type":34},{"date":575,"type":21},"2026-03",{"date":577,"type":21},"2029-03",{"name":325,"class":41},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":4,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":22,"phases":588,"briefSummary":589,"conditions":590,"keywords":598,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":612},"100572695","phase-2-a-study-of-circulating-tumor-dna-ctdna-testing-for-people-with-b-cell-lymphoma-100572695","NCT06736613","A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma","Cerebral Spinal Fluid Circulating Tumor DNA (ctDNA) Analysis in Patients With Aggressive B-cell Lymphoma Receiving Front Line Therapy and at High Risk for Central Nervous System Relapse","Inclusion Criteria:\n\n* Signed Informed Consent.\n* Ability and willingness to comply with the requirements of the study protocol.\n* Age ≥ 18 years old.\n* Diagnosis of the following histologies according to the 2016 WHO Classification for Mature Lymphoid Neoplasms81 along with a specific high-risk criteria for CNS relapse if indicated as certain diagnoses in of themselves are high-risk alone:\n\n  1. Diffuse Large B-cell Lymphoma (DLBCL) with CNS IPI score ≥ 4.\n  2. Stage III\u002FIV High Grade B-cell lymphoma (HGBCL) with MYC, BCL2, and\u002For BCL6 translocations\n  3. Primary DLBCL of Breast\n  4. Primary DLBCL of Testis\n  5. Primary Cutaneous DLBCL, Leg Type\n  6. Intravascular Large B-cell Lymphoma\n  7. Stage III\u002FIV HIV-associated DLBCL\n  8. Double expressor DLBCL (co-expression of MYC ≥ 40% and BCL2 ≥ 50% without translocations) with a CNS IPI score ≥ 3\n  9. DLBCL with the following extranodal involvement AND CNS IPI score ≥ 3:\n\n  i. Adrenal ii. Breast iii. Bone Marrow with pathological overt morphological involvement iv. Epidural\u002FParaspinal v. Nasal\u002Fparasinus with local invasion such as bone destruction vi. Renal viii. Uterine ix. Testis xi. Skull involvement without direct invasion into CNS\u002Fbrain parenchyma\n* Transformed DLBCL from any indolent B-cell lymphoma is permitted (as long as there is no prior history of CNS involvement).\n* Planned to receive standard chemoimmunotherapy.\n* Patient is able to undergo lumbar puncture without any contraindications which include but are not limited to altered mental status, increased intracranial pressure due to any CNS lesion (mass, abscess), overlying skin infection at the site of LP, inability to safely access CSF due to lymphomatous involvement (i.e. epidural mass), or inability to hold antiplatelet or anticoagulation safely for the procedure to be performed.\n* No systemic therapy prior to study enrollment for an aggressive B-cell lymphoma is permitted. Treatment for a history of indolent lymphoma is permitted. Systemic corticosteroids are permitted (must be ≤7 days and tapered down to prednisone ≤ 20 mg oral\u002Fday or steroid equivalent by first day of anthracycline treatment). Clinical exceptions in regards to steroid management can be made after discussion with PI.\n* ECOG performance status of 0 to 2.\n\nExclusion Criteria:\n\n* Active systemic therapy for another malignancy (other than indolent B-cell lymphoma) within 2 years; local\u002Fregional therapy with curative intent such as surgical resection or localized radiation within 2 years of treatment is permitted.\n* Active concurrent malignancy with the exception of basal cell or localized squamous cell skin carcinoma, localized prostate cancer, or other localized carcinomas such as carcinoma in situ of cervix, breast, or bladder.\n* Any uncontrolled illness that in the opinion of the investigator would preclude administration of curative intent chemoimmunotherapy (e.g. significant active infections, hypertension, angina, arrhythmias, pulmonary disease, or autoimmune dysfunction).\n* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 2 weeks prior to Cycle 1, Day 1.\n* Psychiatric illness or social situations that would limit the patient's ability to tolerate and\u002For comply with study requirements.",{"count":587,"type":21},50,[104],"The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system\u002FCNS relapse test positive for cerebral spinal fluid\u002FCSF ctDNA but test negative for CNS involvement using standard tests. The study will also look at how often CNS relapse happens in people with and without detected CSF ctDNA.",[375,374,591,592,27,593,594,595,596,597],"Stage III High Grade B-Cell Lymphoma","Stage IV High Grade B-Cell Lymphoma","Intravascular Large B-Cell Lymphoma","Diffuse Large B Cell Lymphoma of Breast","Diffuse Large B Cell Lymphoma of Testis","HIV-associated Diffuse Large B Cell Lymphoma","Double Expressor DLBCL",[375,374,591,592,27,593,594,595,596,599,600,601,602,603],"Double expressor DLBCL","Circulating Tumor DNA","ctDNA","Memorial Sloan Kettering Cancer Center","24-336","2025-12-17",{"date":606,"type":34},"2025-12-18",{"date":608,"type":34},"2024-12-11",{"date":610,"type":21},"2027-12-11",{"name":602,"class":41},7,{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":621,"targetDuration":4,"studyType":22,"phases":622,"briefSummary":623,"conditions":624,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":67},"100512311","phase-1-optimizing-lymphodepletion-to-improve-outcomes-in-patients-receiving-cell-therapy-with-yescarta-100512311","NCT05950802","Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta","Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving CAR T Cell Therapy With Yescarta\u002FAxicabtageNeciloleucel (ODIN)","ODIN","Inclusion Criteria:\n\n1. Age ≥ 18 years at the time of informed consent\n2. Life expectancy ≥ 12 weeks\n3. Biopsy-proven and histologically confirmed R\u002FR large B cell lymphoma, including R\u002FR DLBCL, transformation from FL, and R\u002FR PMBCL.\n4. Radiographically documented measurable disease as per Lugano response criteria (i.e. LDi \\> 1.5 cm that is FDG avid).\n5. At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic cancer therapy at the time the subject provides consent\n6. Eligible for standard of care CAR T cell therapy, specifically, relapsed or refractory large B cell lymphoma after two or more lines of systemic therapy, and subjects must have received adequate first-line therapy including at a minimum:\n\n   * Anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20 negative, and\n   * An anthracycline containing chemotherapy regimen\n7. Patient does not have active CNS disease\n8. Patient is sufficiently stable to facilitate planned CAR T-cell therapy (e.g. not rapidly progressing on temporizing therapy, no significant compromise of vital organ functions (intubation, dialysis, requiring ICU\u002Fvasopressor support)) and has good performance status\n9. ECOG performance status 0 or 1 at enrollment\n10. Patient has not received prior adoptive T-cell immunotherapy\n11. Patient is not HIV positive\n12. Patient did not receive prior allogeneic stem cell transplant\n13. Adequate bone marrow, renal, hepatic, pulmonary and cardiac function\n14. Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential)\n15. Sexually active males who accept to use a condom during intercourse during treatment and for 6 months after treatment as they should not father a child in this period. A condom is required to be used also by vasectomized men (as well as during intercourse with a male partner) in order to prevent delivery of the drug via seminal fluid\n16. Must have an apheresis product of non-mobilized cells accepted for manufacturing.\n\nExclusion Criteria:\n\n1. Persisting disease bulk (defined as ≥10 cm) on restaging imaging following bridging therapy.\n2. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 3 years\n3. History of Richter's transformation of CLL\n4. History of allogeneic stem cell transplant\n5. Received \\\u003C 2 lines of therapy for large B cell lymphoma\n6. Prior CD19 targeted therapy\n7. Subject has received or undergone the following:\n\n   o Therapeutic doses of corticosteroids (defined as \\>20 mg\u002Fday prednisone or equivalent) within 7 days prior to leukapheresis.\n\n   Physiologic steroid replacement, topical, and inhaled steroids are permitted.\n   * Cytotoxic chemotherapeutic agents that are not considered lymphotoxic, and intrathecal (IT) chemotherapy must be stopped ≥ 7 days prior to leukapheresis.\n   * Lymphotoxic chemotherapeutic agents (eg, cyclophosphamide \\> 300 mg\u002Fm2, ifosfamide, bendamustine) 4 weeks prior to leukapheresis.\n   * Experimental agents within 4 weeks prior to signing the ICF, unless no response or PD is documented on the experimental therapy and at least 5 half-lives have elapsed prior to leukapheresis.\n   * Ibrutinib, lenalidomide and PI3K inhibitor within 5 half-lives prior to leukapheresis\n   * Immunosuppressive therapies within 4 weeks prior to leukapheresis (eg, calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolate, rapamycin thalidomide, immunosuppressive antibodies such as anti-tumor necrosis factor \\[TNF\\], anti-IL6, or anti- IL6R)\n   * Radiation within 6 weeks of leukapheresis. Subject must have progressive disease in irradiated lesions or have additional nonirradiated, PET-positive lesions to be eligible. Radiation to a single lesion, if additional non-irradiated PET-positive lesions are present, is allowed up to 2 weeks prior to leukapheresis (discuss with sponsor).\n   * Treatment with systemic immunostimulatory agents (including but not limited to interferon and IL-2) within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to the infusion of axicabtagene ciloleucel\n8. Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy\n9. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous (IV) antimicrobials for management. Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment.\n10. Known history of infection with human immunodeficiency virus (HIV) or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive). If there is a positive history of treated hepatitis B or hepatitis C, the viral load must be undetectable per quantitative polymerase chain reaction (PCR) and\u002For nucleic acid testing.\n11. Active tuberculosis\n12. Presence of any indwelling line or drain (eg, percutaneous nephrostomy tube, indwelling Foley catheter, biliary drain, or pleural\u002Fperitoneal\u002Fpericardial catheter). Dedicated central venous access catheters such as a Port-a-Cath or Hickman catheter are permitted\n13. Subjects with detectable cerebrospinal fluid malignant cells or known CNS involvement; a history of prior treated CNS lymphoma which is not active at the time of relapse is permitted\n14. History or presence of significant non-malignant CNS disorder such as seizure disorder, cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement\n15. Subjects with cardiac atrial or cardiac ventricular lymphoma involvement\n16. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, New York Heart Association Class II or greater congestive heart failure, or other clinically significant cardiac disease within 12 months of enrollment\n17. Requirement for urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression\n18. History of autoimmune disease, requiring systemic immunosuppression and\u002For systemic disease modifying agents within the last 2 years.\n19. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis per chest computed tomography (CT) scan at screening. History of radiation pneumonitis in the radiation field (fibrosis) is allowed.\n20. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment\n21. Any medical condition likely to interfere with assessment of safety or efficacy of study treatment\n22. History of severe immediate hypersensitivity reaction to tocilizumab or any of the agents used in this study\n23. Treatment with a live, attenuated vaccine within 6 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study\n24. Women of childbearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of chemotherapy on the fetus or infant.\n25. Subjects of either sex who are not willing to practice birth control from the time of consent and at least 6 months after axicabtagene ciloleucel infusion\n26. In the investigators judgment, the subject is unlikely to complete all protocol- required study visits or procedures, including followup visits, or comply with the study requirements for participation.",{"count":102,"type":21},[187],"This is a Phase 1b study of participants with Diffuse Large B Cell Lymphoma (DLBCL). The purpose of this study is to identify an optimized lymphodenpletion (LD) regimen by evaluating standard and intermediate doses of Fludarabine (Flu) \u002F Cyclophosphamide (Cy) with or without a fixed dose of total lymphoid irradiation (TLI) in the setting of standard of care CAR T cell therapy.",[27],"2025-12-04",{"date":627,"type":34},"2025-12-08",{"date":629,"type":34},"2023-07-14",{"date":631,"type":21},"2027-09",{"name":633,"class":41},"University Health Network, Toronto"]